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Rationale: Antipsychotic polypharmacy (APP) appears to be a common practice worldwide despite treatment guidelines 
advising against the practice for most patients in view of lack of evidence and possible risk of harm.  Our study aimed to 
address deficiencies in local and international research by examining the current prevalence of APP in a South African 
context and investigating a broad range of patient, illness and treatment characteristics that may be associated with the 
practice. In doing so, we aimed to provide an indication of possible areas to be addressed in order to improve local mental 
health care practice.  
 
Methods: We conducted a cross-sectional study of discharge records using Valkenberg Hospital’s electronic patient 
database.  We collected data on patient, illness and treatment characteristics for patients discharged on one or more 
antipsychotic agent from January to June 2014. Hierarchical multivariable logistic regression analysis was conducted to 
assess the relationship between APP and demographic and clinical variables and prescription patterns were analysed.  
 
Results: Discharge records of 565 patients were examined. The prevalence of APP in our study population was 29.03% 
(95% CI= 25.31%-32.96%). Analysis of demographic and clinical characteristics revealed that age>29, male sex, diagnosis of 
schizophrenia compared to bipolar and substance-induced disorders, co-morbid intellectual disability, co-morbid substance 
use, greater number of hospital admissions and high-dose prescribing were significantly  associated with APP. While 
highest rates of APP in patients with schizophrenia and schizoaffective disorders occurred, APP was also observed in a 
number of patients with bipolar and substance-induced disorders. Prescription patterns demonstrated the prominent use 
of first-generation antipsychotics and long acting injectables in APP combinations. Patients receiving APP were significantly 
more likely to have anticholinergic agents and sodium valproate co-prescribed in their treatment regimen.  
 
Discussion: The prevalence of APP found in our study is fairly high in comparison with international rates.  Antipsychotic 
prescription patterns reflect a complex interplay among patient, illness and treatment characteristics of our population. 
Our findings indicate that patients receiving APP may be those with greater illness severity, complexity, chronicity and 
treatment resistance, with complicating factors including co-morbid substance use involved.  While APP is most common in 
patients with schizophrenia, antipsychotics may also be used in combination to manage mood and psychotic symptoms in 
patients with schizoaffective, bipolar and substance-induced disorders.  The frequent use of long acting injectables in 
combinations may suggest concern over compliance in our population. The positive associations of APP with high-dose 
prescribing and co-prescription of anticholinergic medication contributes to concern over the safety of APP. 
 
Conclusion Our study suggests concern over current local practice in that combination antipsychotic agents were 
prescribed for a number of patients with a range of psychiatric diagnoses without sufficient evidence for efficacy of this 
practice and at possible cost of increased adverse effects.  Additional research is needed examining the practice of APP 
across diagnoses, focusing on the multiple aspects affecting local practice and various contributing factors that could be 
targeted for intervention.  This would be a positive step towards improving the quality of our service and providing optimal 
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Chapter 1:   Research Protocol and Literature review 
 




The term antipsychotic refers to a group of agents that have a variety of actions, with individual 
antipsychotic drugs possessing various properties, including antipsychotic, antimanic and mood-
stabilizing properties.(1)  Antipsychotic agents are used in the treatment of psychotic and mood 
disorders. They have demonstrated efficacy in acute episodes of schizophrenia and for maintenance 
treatment by reducing the risk of relapse.(2) Clinical practice guidelines for the treatment of 
schizophrenia (2-6) advocate an approach of antipsychotic monotherapy in the majority of cases.  
They recommend avoiding antipsychotic polypharmacy (APP) which can be defined as co-
prescription of more than one antipsychotic drug for a given patient,(7) except for short periods 
when switching agents or in treatment resistant settings when augmentation of clozapine with 
another antipsychotic agent may be considered, although supporting evidence for this remains 
weak.(8) Treatment guidelines recommend use of certain antipsychotics as first-line treatment 
options for acute mania, acute bipolar depressive episodes and for long-term 
maintenance/prophylactic treatment in bipolar disorder.(9,10) In bipolar patients with residual 
symptoms or frequent relapses on antipsychotic treatment, these guidelines advocate switching to 
an alternative monotherapy, or using an antipsychotic agent in combination with a mood stabilizer 
(lithium or sodium valproate).  APP is not recommended in bipolar disorder. Use of antipsychotic 
agents in the treatment of psychosis with coexisting substance misuse (dual diagnosis) is advised in 
accordance with guidelines on schizophrenia or bipolar disorder.(13)  
 
Despite treatment guideline recommendations, APP appears to be a common practice worldwide. 
APP rates range between 10 – 50 % in different settings.(14-19) A previous systematic review 
examined the prevalence and correlates of APP looking at studies published between 1970 to 2009 
from different geographical regions.(20) This review found that global rates of APP remained similar 
over time (decades), with a median prevalence rate of APP of 19.6%.  However, there were 
significant differences in rates of APP across geographical regions. APP rates in Asia and Europe were 
found to be consistently higher compared to Oceania and North America for the past four decades. 
The pooled median APP rate across decades for Asia was 32% (interquartile range 19.2% - 53.0%), 
with Europe’s rate being 23% (interquartile range 15.0 % - 42.1%), compared to Oceania with a 
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median rate of 16.4% (interquartile range 9.8% - 20.0%) and North America with a median rate of 
16% (interquartile range 7.2% - 24.4%). Rates of APP showed different trends across time in different 
regions. The rates in North America increased progressively from 12.7% in the 1980s to 17.0% in the 
2000s, as did the rates in Europe with an increase from 17.6% in the 1980s to 26.3% in the 1990s 
and then a plateau to 25% in the 2000s. The rates in Oceania showed a large increase in APP from 
2% in the 1980s to 17.7% in the 2000s. In contrast, rates of APP in Asia decreased substantially from 
55.5% in the 1980s to 19.2% in the 2000s. Reasons for geographical differences and trends across 
time remain uncertain.(20)  
 
While substantial rates of APP have been described, there is a lack of robust evidence to support the 
routine use of combined antipsychotics.(7,8,21-23) Evidence in support of antipsychotic combination 
therapy in schizophrenia consists mostly of small, open-label studies and case series,(7,8,21,23-26) 
although randomized controlled trials on the subject have also been conducted. A meta-analysis 
published in 2009 reviewed evidence from 19 randomized controlled trials that compared 
antipsychotic monotherapy to co-treatment with a second antipsychotic in patients with 
schizophrenia.(23) Findings suggested that, in certain clinical situations, APP may be associated with 
superior benefit compared with monotherapy regarding all-cause discontinuation and general 
measures of efficacy. However, much of the evidence in support of combination treatment came 
from clozapine augmentation studies, many conducted in China.  The authors acknowledged there 
was evidence of publication bias supporting positive results and that database was too 
heterogeneous to derive strong clinical recommendations. In addition, it is not possible to determine 
whether improvement was due to potentiation or additive dosage effect.(27) Another meta-analysis 
of antipsychotic augmentation studies of clozapine only found benefit of APP in open, but not in 
blinded studies.(8) A recent well-designed randomised controlled trial of aripiprazole augmentation 
of risperidone or quetiapine showed no improvement in symptoms in patients receiving combined 
antipsychotic treatment compared to monotherapy. (28) Research on efficacy of APP in disorders 
other than schizophrenia is lacking.    
 
In addition, there is evidence for harm associated with APP. A previous systematic review examined 
the safety and tolerability of this practice.(29) Findings from this review and other studies suggested 
an association of APP with increased adverse effects compared to treatment with one antipsychotic 
agent. The evidence was strongest with regard to increased extrapyramidal side-effects (17,30,31) 
and hyperprolactinaemia.(32-34) These side-effects were likely related to higher total antipsychotic 
dose. APP was also associated with increased sexual dysfunction,(35) hypersalivation,(36) 
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sedation,(32) cognitive impairment,(37) glucose elevation,(38) diabetes,(39,40) metabolic 
syndrome(41,42) and possibly dyslipidaemia.(40,41) Evidence for weight gain was mixed.(38,40,43) 
The exception to this trend of increased side-effects associated with APP came from some studies on 
aripiprazole augmentation of another antipsychotic agent which found a decrease in certain side-
effects including hyperprolactinaemia, sexual dysfunction, weight gain and dyslipidaemia in 
particular settings.(43-45) Studies examining QTc prolongation presented different outcomes.(34,46) 
Of concern was the finding of increased risk of sudden cardiac death associated with APP and further 
increased by higher doses found in a large database study.(47) Studies reporting on association of 
APP and mortality produced conflicting results but of concern were results of increased mortality 
demonstrated in two cohort studies.(48,49)  Additional concerns relating to APP include drug-drug 
interactions, problems in determining cause and effect of different combined treatments, decreased 
compliance as a result of complex drug regimens and significantly greater cost.(50) 
 
Research has been conducted in order to gain insight into factors contributing to the practice of APP 
despite the adverse risk/benefit evidence. Antipsychotic prescription patterns seem to reflect a 
complex interplay among patient, illness, treatment and prescriber factors.(50) A previous 
systematic review conducted an evaluation of relevant correlates of APP, focussing on these 
factors.(50) This review and other studies found that patient characteristics associated with APP 
were younger age,(14,30,51-55) male sex (16,18,20,51,56) and unmarried patients,(30,51,57) with 
mixed results from studies examining race.(44,48,50,52,58) Illness variables associated with 
increased APP included diagnosis of schizophrenia or schizoaffective disorder,(18,20,51,55,56) 
earlier age of onset,(31,55,59) longer duration of illness,(16,20,60,61) greater illness 
severity,(51,54,55,59-61) treatment resistance,(60,61) psychiatric comorbidity,(56) mental 
retardation (55) and mixed results from only a few studies for comorbid substance use.(30,54,55)  
With regard to treatment variables, APP was found to be associated with inpatient 
setting/hospitalization,(20,30,62) longer inpatient stay,(18,31) APP at baseline,(51,61) higher total 
dose of antipsychotic,(7,14-16,31,55,63) treatment with quetiapine,(15,31,42,63) use of long acting 
injectables (LAIs),(17,20,64) first-generation antipsychotic (FGA) treatment,(16,20,37,55) 
anticholinergic treatment,(7,20,30,42,64) with mixed evidence regarding antidepressant 
treatment,(18,30,55,59) anxiolytic treatment (30,55,59) and mood stabilizer treatment.(30,55) 
Combinations of FGAs and second-generation antipsychotics (SGAs) were most common in studies 
on APP,(15,19,20) although studies reporting greater use of FGA combinations as well as SGA 
combinations were also found.(17,53) Provider variables including healthcare policies, drug 
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availability and cost, psychiatric education and experience and prescriber preference also influenced 
rates of APP.(65,66) 
 
There is a paucity of research on APP in South Africa. Only one previous study has examined 
antipsychotic prescription patterns in a South African setting.(67) This study was published in 2008 
and reviewed data on antipsychotic drug prescriptions for Xhosa patients with schizophrenia and 
schizoaffective disorder in three catchment areas in the Western Cape, particularly in terms of 
clozapine use. At the time of data collection FGAs were the only first line treatment available for use 
in the public sector in the Western Cape and clozapine the only freely available SGA. This study 
found that there was an overall low rate (10%) of clozapine use and a relatively high frequency of 
APP (28.6% of patients). The lower than expected rate of clozapine use could possibly be related to 
clinician concerns about treatment adherence, side-effect profile and the need for regular leukocyte 
counts to monitor the risk of agranulocytosis, a monitoring requirement that may be problematic in 
a low resource setting.(67)  High rates of APP may be partially explained by high rates of LAI use 
(49.4% of patients), with the most frequently used antipsychotic combination being haloperidol and 
a LAI (54.2% of combinations). The study did not examine rates of high-dose antipsychotic usage. It is 
likely that there have been significant changes in antipsychotic drug prescriptions in the Western 
Cape since the time of this study as several additional SGAs have become widely available in the 
South African public sector and are commonly used in clinical practice. This may have resulted in an 
increase in rates of APP in view of research findings that use of SGAs is common in APP as previously 
discussed.  
 
As evident above, APP is a practice generally viewed in the context of schizophrenia.  Previous 
research into APP commonly restricts the study to a specific psychiatric population, usually patients 
with diagnosis of schizophrenia, or sometimes examines APP broadly across all patients prescribed 
antipsychotic treatment, without accounting for different psychiatric diagnoses included in this 
population.(56)  While studies examining the relative prevalence of APP by diagnosis are limited, 
some research has adopted this approach.  These studies confirmed that rates of APP are highest in 
patients with a diagnosis of schizophrenia, but also found varying lower rates of APP in patients with 
schizoaffective disorder and bipolar disorder.(14,27,30,55,68) To the best of our knowledge there is 
a lack of research investigating the occurrence of APP in other diagnoses, such as substance induced 
disorders, with this diagnosis either being excluded from studies as a primary diagnosis or not 
mentioned. Only a few studies reported on comorbid substance abuse and these produced mixed 




Our study attempted to address deficiencies in local and international research by examining recent 
antipsychotic prescribing patterns across diagnoses. It included information on comorbid conditions 
such as substance abuse, as well as other patient, illness and treatment characteristics associated 
with APP, including high-dose prescribing. This allowed for development of greater insight into the 
prevalence of and factors associated with APP in a hospital population in the Western Cape, 




APP was defined as the prescription of any two or more antipsychotics (oral and LAIs included) on 
discharge from hospital in the same patient.  
 
1.3 Study aims 
 
 To determine the prevalence of APP in patients discharged from Valkenberg Hospital.  
 To determine the patient, illness and treatment factors associated with APP compared to 
monotherapy. 
 
1.4 Study objectives 
 
 We used an electronic patient record database to obtain information on patients prescribed 
one or more antipsychotic agent at time of discharge and used this information to 
determine the prevalence of APP in our study population.  
 We used an electronic patient record database to obtain information on socio-demographic 
and clinical variables of patients in our study population in order to assess the patient and 
illness factors that may be associated with APP. 
 We examined the nature and extent of pharmacotherapies prescribed to these patients 
from information on the electronic patient record database in order to assess related 




Based on previous research we hypothesized that: 
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 There would be a fairly high rate of APP in our study population.   
 The current rate of APP may be higher than that seen in previous years as several additional 
SGAs have recently become widely available in the South African public sector and are 
commonly used in clinical practice.  
 Compared with monotherapy, APP would be more likely to occur in patients of younger age, 
male sex and single/unmarried patients. 
 APP would be more likely in patients with diagnosis of schizophrenia, comorbid psychiatric 
diagnosis, comorbid substance use disorders, long length of hospital stay, increased number 
of hospital admissions, and longer time from first hospitalization to most recent discharge.  
 Compared to patients with schizophrenia, lower rates of APP would be found in patients 
with schizoaffective disorder, bipolar disorder and substance induced disorders but these 
disorders would contribute significantly to the prevalence of APP in our population.  
 APP would be positively associated with treatment variables of FGA use, use of LAIs, FGA-
SGA combinations, high dose prescribing, concomitant anticholinergic use and possibly co-
prescription of mood stabilizer and benzodiazepines. We expected antidepressant use to 




1.6.1 Study design 
 
We conducted a cross-sectional study of discharge records using Valkenberg Hospital’s electronic 
patient record database, Clinicom.  
 
1.6.2 Study setting 
 
Valkenberg Hospital is a large, government-funded psychiatric hospital in the suburb of Observatory, 
in Cape Town, South Africa.  The hospital provides psychiatric services to the Cape Peninsula and is a 
major specialist referral centre of the Western Cape Province. It is the principal teaching hospital for 
the University of Cape Town’s Department of Psychiatry. The hospital currently comprises 340 
inpatient beds, of which 200 are dedicated to acute psychiatric services, 125 to forensic psychiatric 
services and 15 to a smaller therapeutic component. Patients admitted to the acute psychiatric units 
are commonly involuntary admissions with severe mental illness posing a risk to themselves or 





1.6.3 Study population 
 
We reviewed information on patients discharged from Valkenberg Hospital’s acute and therapeutic 
units. We included patients with non-affective psychotic disorders and major affective disorders 
prescribed one or more antipsychotic agents at time of discharge. We included patients with 
diagnoses of schizophrenia (F20), acute and transient psychotic disorder (F23), delusional disorder 
(F22), schizoaffective disorder (F25), bipolar disorder (F31) and substance-induced mood and 
psychotic disorders (F10 - F19). We excluded patients with primary diagnoses relating to a medical 
condition, dementia, anxiety disorder, major depressive disorder, intellectual disability or 
personality disorder as these diagnoses were unlikely to feature significantly in our study population 
or contribute meaningfully to rates of APP in our setting.  We examined the 6 month time period of 
January 2014 to June 2014. We estimated a total sample size of approximately N=500 to be 
sufficient as previous research in South Africa used a sample of 510 patients and international 
research on the subject has used study populations ranging from low hundreds to many thousands 




We accessed discharge records on Valkenberg hospital’s electronic patient record database, 
Clinicom, to attain data on the variables below. We extracted the data on an electronic data 
collection sheet. 
 
(a) Patient variables 
 
 Age – number in years  
 Gender – male or female 
 Marital status – single, married, divorced, widowed 
 Occupation – employed, unemployed 
 
(b) Illness variables 
 
 Diagnosis – recorded from ICD-10 coding in database 
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 Comorbid psychiatric diagnosis – gathered both from ICD-10 coding and information contained 
in discharge summaries completed electronically for each patient by their attending psychiatric 
registrar at time of discharge. Where the attending case manager commented on the presence 
of significant co-existing depressive symptoms, anxiety symptoms, evidence of personality 
disorder or traits or mild intellectual disability, these were captured as psychiatric comorbidities. 
 Comorbid substance abuse – gathered from ICD-10 coding and clinical descriptors within patient 
discharge summaries; included comorbid alcohol (F10), cannabis (F12), methamphetamine 
(F15), methaqualone (F13), heroin (F11) and cocaine (F14) misuse 
 Length of stay in hospital – number of days; as a proxy indicator of illness severity  
 Number of Valkenberg hospital admissions – as a proxy indicator of illness severity  
 Time from first hospitalization at Valkenberg Hospital to most recent discharge – number of 
days; indicator of duration of illness or time in treatment number of days/months 
 
(c) Treatment variables 
 
 Antipsychotic agent(s) prescribed 
 Type of antipsychotic agent – FGA or SGA. Agents classified in our FGA group included 
haloperidol, chlorpromazine, trifluoperazine, flupentixol, zuclopenthixol and fluphenazine. SGA 
agents included amisulpiride, clozapine, olanzapine, risperidone, quetiapine and aripiprazole.    
 Prescribed daily dose (PDD)/Defined daily dose (DDD). To compare doses of different 
antipsychotic drugs, the prescribed daily dose (PDD) in milligrams was divided by the defined 
daily dose (DDD) to give a PDD:DDD ratio. The DDD is defined as the assumed average 
maintenance dose per day for a drug used for its main indication in adults.(69)  For LAIs, the DDD 
is based on the average recommended dose divided by the dosing interval.(69) This is the 
standard international unit recommended by the World Health Organization for drug utilization 
studies.(69) In keeping with previous studies, the PDD/DDD ratio for APP was calculated as the 
sum of the individual PDD/DDD ratios of all antipsychotics prescribed to a patient and high dose 
prescribing was defined as PDD/DDD of greater than 1.5.(15,58,61,70)   
Note: Literature suggests three methods for calculating antipsychotic dose: Chlorpromazine 
equivalents, percentage of British National Formulary (BNF) maximum dose, and Defined Daily Dose 
(DDD).(58) Recent studies have shown that there is coherence between these different methods and 
all are reliable ways for standardizing antipsychotic doses in drug utilization research.(58,71)  
However, the use of Chlorpromazine equivalents methods has disadvantages in that values differ 
across literature (72) and may be of limited accuracy for atypical antipsychotics.(58,73)  The BNF 
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method uses recommended maximum doses from the British National Formulary which may differ 
from those in other countries and are not internationally adopted.(58) The DDD method was chosen 
for this study because it uses values published by the WHO and is widely available and 
internationally recognized as a reliable tool.(58,69)   
 Route of administration -  oral or LAI 
 Co-prescription of mood stabilizer(s) 
 Co-prescription of antidepressant(s) 
 Co-prescription of benzodiazepine(s) 
 Co-prescription of anticholinergic(s) 
 
1.7 Data analysis 
 
We inspected data for normality using histograms and Shapiro Wilks’ test for normality. Continuous 
variables were analysed using student’s t-test for normal data and Wilcoxon-ranksum test for 
skewed data. For categorical variables we used Chi-square tests to analyse data, with Fisher’s exact 
test where appropriate. Confidence intervals for prevalence rates were calculated using the normal 
approximation of the binomial distribution.  
 
The main outcome of interest was the presence of antipsychotic polypharmacy (APP), as previously 
defined. We coded a positive outcome (i.e. the presence of APP) as “1” and a negative (no APP) as 
“0”. We conducted a hierarchical multivariable logistic regression analysis in order to model the 
response variable of antipsychotic polypharmacy as a function of a number of demographic and 
clinical variables. Independent (predictor) variables were categorised into multilevel categorical 
variables using dummy coding to obtain reference level categories. Cut-points for continuous 
variables were decided on the basis of what constituted meaningful clinical categorisations.  We 
followed a forward selection and backward elimination procedure and determined model fit using a 
combination of Likelihood-ratio Chi-square tests and the Akaike Information Criterion (AIC). We 
entered each variable into the model one at a time starting with demographic and then clinical 
variables. We removed variables one at a time if model fit did not improve by their addition, based 
on the likelihood Chi-square tests and AIC. The final model included all variables except reported 
symptoms of anxiety and depression and length of inpatient stay. Model fit for the final model was 
determined using the Pearson Chi-Square Goodness of Fit test. Statistical significance was set at 




1.8 Structured literature review for studies on APP 
 
In order to examine previous research on the prevalence and relevant correlates of APP we 
conducted an electronic search in PubMed (last updated September 2015) using the following key 
words: “(antipsychotic OR antipsychotics OR neuroleptic OR neuroleptics) AND (polypharmacy OR 
combination OR polytherapy) AND (prevalence OR correlates OR association).” In addition, reference 
lists from retrieved articles and relevant reviews were inspected to identify additional studies.  
 
Inclusion criteria were human subjects, English language, adult population (age 16-65 years), articles 
published in peer reviewed journals, articles reporting explicitly of prevalence of APP in the study 
population and articles that reported explicitly on associations between APP and patient, illness and 
treatment characteristics.  No restriction was placed on publication years included in the search. We 
excluded articles not conducted in English, studies in paediatric or geriatric populations, articles 
published in non-peer reviewed journals, intervention studies aimed at decreasing APP and studies 
reporting on psychotropic polypharmacy, without specific mention of APP.  
 
Articles were first analysed in tabular format. Study findings pertinent to our review were 
documented. The quality of articles was assessed in accordance with STROBE guidelines.(74)  Study 
design, population and methods were examined. Limitations affecting quality of research were 




 Restricting the study population to patients discharged from Valkenberg hospital may have 
produced results that are not readily generalizable to the general population in view of previous 
findings of hospitalization being associated with APP.(20,30,62)  
 While discharge prescriptions should have reflected the plan for ongoing maintenance 
treatment in most patients, some APP may have resulted from certain patients discharged 
during a process of cross titration while changing antipsychotic agents. 
 The variables examined in our study were limited to information captured on the hospital’s 
electronic patient record database, Clinicom. We anticipated that data may be incompletely 
captured in some cases. In addition, we realized that certain relevant variables may not be 
directly recorded. We attempted to overcome this problem by examining related variables. 
Length of time from first hospitalization to most recent discharge was used to provide some 
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indication of duration of illness or time in treatment, although we acknowledge that the patient 
may have been diagnosed with mental illness prior to first hospital admission. Number of 
previous admissions and length of stay were recorded as indicators of illness severity and 
possibly treatment resistance, although we realize that these are not direct substitute measures.  
 Our literature search was not exhaustive as it was limited by search terms and the database 
(PubMed) used. We excluded studies not conducted in the English language, which may 
introduce language bias. It was structured literature review and not a comprehensive 
systematic literature review.  
 
1.10 Ethical considerations 
 
1.10.1 Risks and benefits 
 
The study entailed a cross-sectional review of discharge records (ie. secondary data) and did not 
involve direct participation of patients. This removed the risk of possible harm to patients that may 
be involved in studies requiring interaction with participants.  Findings from the study will benefit 
patients in the future by increasing awareness and understanding of the practice of APP and 
identifying possible need for further audits, protocol development on APP practices and need for 
reflection on prescription practices.  
 
1.10.2 Privacy and confidentiality  
 
We made use of the data captured on Valkenberg Hospital’s electronic patient record database in 
such a way that patient privacy and confidentiality was ensured.  We used a password protected 
computer and ensured safekeeping of non-electronic related documents so that the researcher 
alone had access to patient information. Patient identifying data was removed prior to data analysis 
to safeguard patient privacy and confidentiality.  
 
1.10.3 Ethical and regulatory compliance  
 
We conducted the study in accordance with the ethical principles that are contained in the World 
Medical Association Declaration of Helsinki (75) and in the Department of Health’s document, Ethics 
in Health Research, Principles, Structures and Processes.(76)  We attained approval from the 
University Of Cape Town Faculty Of Health Sciences Human Research Ethics Committee, the Faculty 






We made use of Valkenberg Hospital’s electronic patient record database, Clinicom, to attain 
relevant data for our study. The principle researcher captured the data and her supervisor assisted 
with data analysis. We made use of existing resources and did not require additional funding.   
 
1.12 What happens at the end of the study? 
 
By conducting this study we demonstrated the prevalence and patterns of APP at Valkenberg 
Hospital. We were able to assess whether current clinical practice is comparable with standard 
international guidelines and trends using this information. In addition, we identified the patient, 
illness and treatment characteristics that may be associated with APP in our setting. This provided an 
indication of possible areas that need to be addressed in order to improve local mental health care 
practice and enhance safe and effective patient management in the future. We aim to disseminate 
the study findings through public lectures to health professionals and publication in peer-reviewed 
journals. 
 
1.13 Timeline for study 
 
February – June 2014: Protocol development, protocol presentation (3 June)  
June – December 2014: Attain approval, literature review, data collection 
January – June 2015: Data collection 
June – December 2015: Data analysis and report development 
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The objectives of the structured literature review were as follows: 
 To assess the prevalence of antipsychotic polypharmacy (APP) in previous international 
literature. 
 To assess the patient, illness and treatment characteristics associated with APP in previous 
international literature.  
 
2.2 Literature search strategy 
 
We conducted an electronic search in PubMed for prevalence and correlates of APP (last updated 
September 2015) using the following key words: “(antipsychotic OR antipsychotics OR neuroleptic 
OR neuroleptics) AND (polypharmacy OR combination OR polytherapy) AND (prevalence OR 
correlates OR association).” In addition, reference lists from retrieved articles and relevant reviews 
were surveyed to identify additional studies.   
 
2.2.1 Inclusion criteria 
 
 Human subjects 
 English language 
 Adult study population (18 – 65 years) 
 Articles published in peer reviewed journals 
 Articles reporting explicitly on prevalence of APP (co-prescription of more than one 
antipsychotic drug for a given patient) in study population 
 Articles reporting explicitly on associations between APP and patient, illness and treatment 
characteristics. These included observational studies with cross-sectional, case control or 
cohort design and previous systematic reviews.  
 Any study published prior to September 2015 (no restriction placed on publication years 
included) 
 




 Not in English 
 Paediatric or geriatric study population 
 Articles published in non-peer reviewed journals 
 Intervention studies aimed at decreasing APP 
 Studies reporting on psychotropic polypharmacy, without specific mention of APP 
 




2.4 Appraisal of quality and relevant content of studies 
 
Articles included in our review were first analysed in tabular format (Annexure 1). The quality of 
articles was assessed in accordance with STROBE guidelines.(1) Study design was examined as 
different levels of evidence and advantages/disadvantages are associated with different study 





reviewed: 85  
Articles included in 
literature review: 39 
Total number of articles 
included in literature 
review: 47  
Additional articles identified from 
reference lists of articles included in 
literature review: 8 
46 articles excluded: 
1. Did not fully meet inclusion criteria 
2. APP intervention studies aimed at decreasing APP 
3. Reported on psychotropic polypharmacy without specific 
mention  on APP 
893 articles excluded on abstract: 
1. Paediatric or geriatric study population 
2.  Published in non-peer reviewed journals 
3.  Did not comment on prevalence of APP or on patient, illness or 
treatment characteristics associated with APP   
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designs.  Study population was reviewed, with population factors including study size, duration of 
study and method of sampling affecting quality of studies. Statistical methods used in data analysis 
were explored in order to assess for measures taken to reduce the effects of confounders and reflect 
strength of associations. Limitations affecting quality of research were commented upon. Study 
findings pertinent to our review were documented.   
 
2.5 Results  
 
We attained a search result of 978 hits using our key words: “(antipsychotic OR antipsychotics OR 
neuroleptic OR neuroleptics) AND (polypharmacy OR combination OR polytherapy) AND (prevalence 
OR correlates OR association)” after the filters of human population and English language were 
applied. We excluded 893 studies on abstract level when it became apparent that the studies were 
conducted in paediatric or geriatric study populations, published in non-peer reviewed journals or 
did not comment on the prevalence of APP or on patient, illness or treatment characteristics 
associated with APP. We thus reviewed 85 full-text articles. An additional 46 of these were excluded 
because they did not fully meet inclusion criteria, were found to be intervention studies aimed at 
decreasing APP or reported on psychotropic polypharmacy without specific mention on APP. 39 
studies remained appropriate for our literature review. We identified 8 additional relevant studies 
from the reference lists of these articles, which resulted in a total of 47 studies included in our 
literature review. Table 1 provides an overview of the relevant content and quality of studies 
included in our review.   
 
2.5.1 Quality of included studies 
 
Several limitations affecting the quality of literature were found across a number studies (see Table 
1). The majority of studies were cross-sectional in design, which prevented assessment of treatment 
changes over time, with factors such as switching between antipsychotic agents possibly influencing 
results. Many studies were limited in available data due to their retrospective nature. In several 
studies, APP data was included but was not the main focus of the research conducted. Other factors 
limiting quality of studies included small sample sizes, limited duration of studies and restricted 
study populations, affecting validity and generalizability. Some studies failed to comment explicitly 
on methods of random selection used to select study population, leaving us unable to exclude 
selection bias. Several studies did not perform adjustment in multivariate analyses on results, with 
confounding factors possibly influencing their findings.  
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2.5.2 Prevalence of APP in previous international literature  
 
Studies included in the literature review reflected a diverse range of settings and revealed varying 
rates of APP. Of the 44 observational studies that reported explicitly on prevalence of APP, 15 were 
conducted in Europe,(2-16) 16 in North America,(17-32) 7 in Asia,(33-39) 4 in Oceania,(40-43) and 2 
in Africa.(44,45) Differences in rates of APP across geographical regions were evident. Prevalence 
rates of APP were highest across Asian studies, ranging from 12% to 78.6%. European studies 
reflected APP prevalence rates between 0% and 67.7%. Studies conducted in Oceania and North 
America generally revealed lower prevalence rates ranging from 14.2% to 43.2% and 0% to 49.3% 
respectively. Only two previous studies conducted in Africa were found, with an APP prevalence rate 
of 7% found in a Nigerian study (44) and 28.6% in a South African study.(45)  
 
The majority of studies in our review reflected APP prevalence rates from 2000 onwards. Several 
studies had a retrospective comparative component examining APP prevalence rates prior to 2000. 
These studies showed a trend of increasing APP from between 1989 into the early 
2000s.(9,14,15,28,30)  Two  studies in our review showed decreasing rates of APP during the 
2000s.(39,42)  
 
Another aspect of study setting influencing APP prevalence rates in our review was inpatient versus 
outpatient treatment. Inpatient studies generally showed higher rates of APP across geographical 
areas and times. Asian studies demonstrated inpatient prevalence rates ranging from 12% to 
78.6%,(34,38,39) compared to rates ranging from 19.2% to 50.4% in outpatient studies.(35-37) 
European inpatient studies revealed APP prevalence rates between 0% and 67.7% (2,6-14) compared 
to rates between 6.3% and 56.2% found across outpatient studies.(3-5,15,16) Studies conducted in 
North America reflected prevalence rates ranging from 0% to 49.3% across inpatient studies 
(18,23,26,30) and 5.7% to 40% in outpatient studies.(17,19-22,24,25,27-29,31,32) The Oceanian 
studies revealed prevalence rates of 43.2% and 31% in inpatient studies (40,41) compared to rates 
ranging from 14.2% to 18.3% in outpatient studies.(42,43)  
 
Study design should also be noted when considering rates of APP. Most studies included in our 
review were cross-sectional.  Studies with longitudinal examination of rates in the same population 





2.5.3 Patient characteristics associated with APP in previous international 
literature  
 
Age, sex/gender and marital status were the patient characteristics most frequently examined in 
studies reviewed. While some studies failed to demonstrate statistical significance with regard to the 
association of age and APP,(3,4,8,10,16,17,19,33,35,37,40,41,46) there were a number of studies 
that provided evidence for the significant association of younger age and 
APP.(6,12,13,26,27,29,31,34,38,39) The majority of studies examining sex/gender found male sex to 
be positively associated with APP. Although the association was non-significant in many 
studies,(3,8,10,12,17,19,21,26,29,31,33-35,38-40,46,47) several studies did reflect a statistically 
significant association of male sex and APP.(6,13,16,27,41) APP was significantly associated with 
being single/unmarried in 4 studies,(3,6,19,31) with one study reflecting a non-significant 
association of marital status and APP.(35)  
 
Other patient characteristics less commonly captured in studies included in our literature review 
were race/ethnicity, living circumstances, education and employment.  Results for race and ethnicity 
were inconclusive. One study showed a positive association with African-American race and APP,(26) 
while another found the association to be negative.(31)  A single study showed increased APP in 
Asians compared to whites.(27) The association of race/ethnicity and APP was non-significant in 
other studies.(17,19,41,47) The few studies that examined living circumstances found no significant 
association with APP.(4,6,46) Likewise, education, occupation and employment generally failed to 
show significant associations with APP.(4,6,35)  
 
2.5.4 Illness characteristics associated with APP in previous international 
literature  
 
While the majority of studies restricted their study population diagnosis, several examined APP 
across different diagnoses. Diagnosis of schizophrenia was most commonly associated with 
APP.(2,6,27,31,41,47) Schizoaffective disorder was found most commonly with APP in one study.(18) 
Some studies adopted broader diagnostic categories and demonstrated a positive association 
between APP and psychotic disorders.(3,26,29,46)  While diagnoses of schizophrenia, schizoaffective 
disorder or psychotic disorders were most prevalent in patients receiving APP, some studies 
demonstrated substantial occurrence of APP in bipolar disorder (6,18,24,26,46) and even some use 
of APP in major depressive disorders, although APP use in major depressive disorders was 
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consistently far lower than other diagnoses.(6,18,24,26,46) No studies specifying APP rates in 
patients with diagnosis of substance-induced disorder were found. 
 
Few studies reported on associations of APP and co-morbidities. One study showed a positive 
association between APP and psychiatric co-morbidity in general.(27)  Another showed a negative 
association between APP and co-morbid depression.(31) No significant association between anxiety 
and APP was found.(31,37) Co-morbid personality disorder was found to be associated with APP in 
one study,(12) with co-morbid mental retardation showing a non-significant relationship with APP in 
the same study. While a single study demonstrated a significant positive association of APP and co-
morbid substance use,(2) other studies failed to show statistical significance of this 
association.(6,12,27)   
 
APP was significantly associated with earlier illness onset in one study (33) and longer illness 
duration in two studies,(34,38) with the relationship being non-significant in another 
three.(10,33,35) Greater illness severity was positively associated with APP in two studies,(6,33) 
however no significant association was seen in others.(4,12,38,47) Positive and negative symptoms 
were significantly associated with APP in one study,(39) but relationships were found to be non-
significant in other studies.(12,33,37)   
 
2.5.5 Treatment characteristics associated with APP in previous international 
literature  
 
Studies included in our review revealed a positive association between hospitalization and 
APP,(12,31,32,47) with increased rates of APP in patients with greater numbers of previous 
admission found in some studies,(10,26,46) although not reaching statistical significance in 
others.(35,37) Longer inpatient stay was significantly associated with APP in four 
studies,(16,40,41,46) with non-significant findings in two.(8,10)  Antipsychotic monotherapy and APP 
on admission (at baseline) were found to be positively associated with APP at discharge in several 
inpatient studies.(4,6,16,46) High-dose prescribing was consistently associated with 
APP,(4,6,13,18,33,35,38,39,41) as was long acting injectable (LAI) antipsychotic use.(2,35,37,39,47)  
First-generation antipsychotic (FGA) use was positively associated with APP in three 
studies.(33,39,47) Neither studies that examined second-generation antipsychotic (SGA) use,(33-




On analysis of APP prescription patterns reflected in articles included in our review, FGA-SGA 
combination treatment was most common,(2,4,7,10-12,14,17,19,20,26,28,47) followed by SGA-SGA 
combinations,(3,13,18,29,32,33,46) then FGA-FGA combinations which predominated in several 
studies.(8,35,44,45)  Two studies that examined combination types over time both demonstrated a 
move from FGA-FGA combinations to more FGA-SGA combination treatment in recent years.(15,39) 
Agents commonly used in combinations varied across studies, with haloperidol,(26,34,44,45) 
chlorpromazine,(17,44) olanzapine,(5,10,29) risperidone (3,5,14,29,33,46) and quetiapine 
(3,13,17,18,29,46) appearing most frequently. There was diversity amongst studies with regard to 
most common agent combinations, with haloperidol-olanzapine,(20,30) risperidone-quetiapine 
(3,5,29) and quetiapine-aripiprazole (18,46) being the only combinations that were found to be most 
prominent in more than one study.  
 
With regards to co-prescribed medications, a consistent positive association of concomitant 
anticholinergic prescription and APP was evident.(35,38,41,47)  APP was found to be significantly 
associated with co-prescription of mood stabilizers in two studies,(18,31) with non-significant results 
in another.(47) Co-prescription of benzodiazepines showed a positive association with APP in two 
studies.(18,31) However, a negative association of APP and benzodiazepine use was found in 
another study.(33) Concomitant antidepressant use was associated with decreased APP in two 
studies,(6,47) with one study showing non-significant findings.(31)   
 
2.6 Discussion  
 
2.6.1 Prevalence of APP in previous international literature  
 
A previous systematic review that examined the prevalence and correlates of APP in studies 
published between 1970 to 2009 from different geographical regions was included in our review.(47) 
This article showed a global median prevalence rate of APP of 19.6% across time with significant 
differences in rates of APP across geographical regions. APP rates in Asia and Europe were found to 
be consistently higher compared to Oceania and North America. The pooled median APP rate across 
decades for Asia was 32%, with Europe’s rate being 23%, compared to Oceania with a median rate of 
16.4% and North America with a median rate of 16%. African studies did not feature in this review. 
While studies included in our review revealed a range of prevalence rates, findings and geographical 




Reasons for geographical differences in rates of APP are not clear. It has been suggested that higher 
rates in Asia may be partially explained by the Asian traditional medicine belief that a mixture of 
medical remedies is superior to a single compound.(48) Higher rates in Europe compared to North 
America could be as a result of higher use of LAIs or additional use of low potency FGAs to replace 
adjunctive benzodiazepines.(47)   Lower rates of APP in Oceania may be related to higher use of 
clozapine in this region.(47)    
 
Our findings of APP prevalence rates increasing over time from 1989 into the early 2000s were also 
in keeping with findings of the previous systematic review referred to above. This previous review 
reflected rates of APP in Europe, North America and Oceania increasing progressively from the 
1980s to the 1990s and into the early 2000s.(47) These increasing trends may have been partly 
related to increased availability of SGAs over time, which broadened treatment options and may 
have been seen as more acceptable to use in combination with other agents with different 
profiles.(47) Two fairly recent studies in our review found decreasing APP prevalence rates as we 
progress further into the 2000s,(39,42) possibly as a result of greater awareness of treatment 
protocols advocating monotherapy and the risks associated with APP.   
 
Additional consistencies with previous literature were our findings of higher APP prevalence rates in 
inpatient studies compared to outpatient studies, with inpatient status being positively correlated 
with APP in numerous previous studies.(47,49) Possible reasons for this include greater illness 
severity in inpatients, inpatients in the process of switching between antipsychotic agents and 
antipsychotics used for behavioural control or sedation in hospitals.(49)   
 
The decreasing rates of APP found in longitudinal studies were commented upon in our findings. 
One reason for this trend may be that cross-sectional studies may reflect inflated prevalence rates of 
APP as a result of capturing patients in the process of switching between antipsychotics, as well as 
antipsychotics prescribed for behavioural or sedation purposes, both in the inpatient and outpatient 
setting.  
 
2.6.2 Patient characteristics associated with APP in previous international 
literature  
 
Our review findings on patient characteristics associated with APP were similar to those of a 
previous systematic review that focussed on correlates of APP.(49)  While this previous systematic 
review was descriptive in nature and did not perform statistical analysis on findings, it suggested 
33 
 
substantial evidence for the positive association of APP with younger age, male sex and unmarried 
patients.  It is possible that younger age at onset could be associated with increased illness severity, 
leading to increased APP in this population. An alternative explanation could be that younger 
patients are undergoing more treatment changes, reflected as increased rates of APP when 
overlapping antipsychotic switches are captured in cross-sectional studies.(49) It has been suggested 
that the association of male sex and APP could be related to greater illness severity, chronicity or 
dangerousness in males.(49) The same may hold for unmarried status, which has been found to be 
associated with both younger age and greater illness severity/chronicity.(49)  Results on race were 
inconclusive in this previous review, and no mention made of other patient factors examined in our 
review, likely as a result of paucity of studies exploring these associations.  
 
2.6.3 Illness characteristics associated with APP in previous international 
literature  
 
Highest rates of APP in patients with diagnoses of schizophrenia/schizoaffective disorder were to be 
expected in view of antipsychotics being the established mainstay of treatment for these disorders. 
The substantial rates of APP in bipolar disorder found in a few studies in our review was of interest 
and may likely be the result of increasing evidence for efficacy and increased use of atypical 
antipsychotics in the treatment of bipolar disorder. There is a need for further studies investigating 
this practice. No studies specified substance-induced disorders amongst diagnoses. There was also a 
lack of studies examining associations with co-morbid conditions. Previous systematic review 
similarly reflected paucity of studies examining APP across different diagnoses and co-morbidity 
associations and recommended future studies pursue these areas.(49) 
 
Our review suggested possible association of APP with earlier illness onset, longer illness duration, 
greater illness severity and more positive and negative symptoms.  These findings are consistent 
with previous systematic reviews that have suggested that illness characteristics demonstrated an 
association of APP with greater illness severity, chronicity and treatment resistance,(47,49) with 
additional antipsychotics added possibly as a result of poor response on monotherapy.  
 
2.6.4 Treatment characteristics associated with APP in previous international 
literature  
 
Similarly to patient and illness characteristics, treatment variables associated with APP have also 
been found to point towards greater illness severity, chronicity and refractoriness,(49) evidenced by 
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our findings of a possible positive association of APP with hospitalization, greater numbers of 
previous admission, longer inpatient stay and high-dose prescribing. It has been suggested that the 
positive association of APP with use of LAIs may result from the difficulty performing fine 
adjustments with LAIs alone, leading to oral medication being added for this purpose.(49) Concerns 
over compliance likely also contribute to the association between APP and LAI prescription.  
 
APP prescription patterns reflected in our review were in keeping with those of a previous 
systematic review, which found a positive association of APP with FGA use, with a move from FGA-
FGA combinations to more FGA-SGA combinations over time and FGA-SGA combination treatment 
being most prevalent.(47) Increased FGA-SGA trends could be explained by wider availability of SGAs 
in recent years which has increased treatment options available to prescribers as a result of their 
more varied pharmacodynamic profiles.(47) Psychiatrists may combine FGA agents with SGA 
antipsychotics with different profiles in hope of better outcomes and fewer extrapyramidal side-
effects.(47)  Prescriber practices vary widely amongst different health care systems and settings,(47) 
likely contributing to the variety of agents found to be used in combination in our review.   
 
Consistent positive association of concomitant anticholinergic prescription with APP reflects an 
increased risk of extrapyramidal side-effects in patients treated with APP. This may be related to our 
findings of the positive associations of APP with high-dose prescribing and FGA use, factors which 
may also increase risk for extrapyramidal side-effects.  The association of APP and co-prescription of 
mood stabilizers may be linked to high rates of APP in schizoaffective disorder,(18) and use of mood 
stabilizers to manage residual mood symptoms, aggression and hostility in difficult patients.(47) Co-
prescription of benzodiazepines may reflect use in this population for sedation and behaviour 
control,(47) but results in this regard have been inconsistent. It has been suggested that 
antidepressants may be used to manage depressive and negative symptoms that may otherwise 
increase APP in a subgroup of patients,(47) possibly explaining the findings of decreased rates of APP 
in patients receiving concomitant antidepressant treatment. Previous review findings regarding 
concomitant medication use were similar to those revealed in our review.(47)   
 
2.6.5 Previous literature on APP in South Africa 
 
Only one previous study has examined antipsychotic prescription patterns in a South African 
setting.(45) This study used data collected between 2002 and 2005 and reviewed antipsychotic drug 
prescriptions for Xhosa patients with schizophrenia and schizoaffective disorder in three catchment 
areas in the Western Cape, particularly in terms of clozapine use. At the time of data collection FGAs 
35 
 
were the only first line treatment readily available for use in the public sector in the Western Cape 
and clozapine the only freely available SGA. This study found that there was an overall low rate of 
clozapine use (10%) and a relatively high frequency of APP (28.6% of patients). The lower than 
expected rate of clozapine use could possibly be related to clinician concerns about treatment 
adherence, side-effect profile and the need for regular leukocyte counts to monitor the risk of 
agranulocytosis, a monitoring requirement that may be problematic in a low resource setting.(45)  
High rates of APP may be partially explained by high rates of LAI use (49.4% of patients), with the 
most frequently used antipsychotic combination used being haloperidol and a LAI (54.2%) of 
combinations). The study did not examine rates of high-dose antipsychotic usage or factors 
associated with APP in their study population. It is likely that there have been significant changes in 
antipsychotic drug prescriptions in the Western Cape since the time of this study as several 
additional SGAs have become widely available in the South African public sector and are commonly 
used in clinical practice.  
 
2.7 Relevance for our study   
 
APP appears to be a relatively common practice worldwide, with geographical location and time of 
study influencing prevalence rates. In contrast to the fairly substantial international literature on 
APP, there is a paucity of research on APP from Africa, with only one previous study examining rates 
of APP in a South African setting conducted in 2008. There is clearly a need for investigation into this 
practice in the current South African health care climate. While inpatient, cross-sectional studies 
may be more feasible to conduct, the influence of clinical setting and study design on prevalence 
rates requires consideration.  
 
There have been no previous studies examining patient, illness and treatment characteristics 
associated with APP in South Africa. Patient, illness and treatment factors associated with APP have 
been examined in previous international literature but inconsistencies and gaps in the evidence 
remain.  Patient characteristics of age, sex and marital status have received most attention, with 
fewer studies examining other patient factors possibly associated with APP. There is a lack of 
information on illness characteristics in the context of APP.  APP is a practice generally examined in 
the context of schizophrenia/schizoaffective disorders, with fewer studies investigating the 
occurrence of APP in bipolar disorder and no previous studies examining APP rates in substance-
induced disorders found. There is a deficiency in the literature on co-morbidities associated with 
APP. Antipsychotic prescriptions seem to vary widely in different contexts and there is a need for 




Our study will attempt to address deficiencies in local and international research by examining the 
current prevalence of APP in a South African context and investigating various patient, illness and 
treatment characteristics that may be associated with the practice. We will examine antipsychotic 
prescribing patterns across diagnoses, including bipolar disorder and substance-induced disorders. 
We will provide information on a broad range of patient, illness and treatment characteristics that 
may be associated with APP, including co-morbid conditions such as substance abuse, high-dose 
prescribing and concomitant psychotropic prescribing. Our study will provide greater insight into the 
prevalence of and factors associated with APP in a study population in the Western Cape, increasing 
understanding of the complexity of the practice of APP in our setting and hopefully offering a 
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Analysis of studies included in literature review according to study design, population, prevalence of antipsychotic polypharmacy (APP), factors associated 
with antipsychotic polypharmacy (APP), most common antipsychotic polypharmacy (APP) combinations and study limitations 
Study Design Population Prevalence of 
APP 
Factors associated with 
APP 
Most common APP 
combinations 
Study limitations 





Inpatients receiving at least one antipsychotic 
agent in March 2012, all diagnoses included, 
Federal Neuropsychiatric Hospital, Uselu, Benin 






Not examined FGA-FGA (haloperidol-
chlorpromazine) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Focused on high-dose prescribing, main focus not APP 
Small study size 
Short duration of study, validity affected 





Outpatients prescribed at least one antipsychotic 
at outpatient visit in 2003-2004 NAMCS and 2003-
2004 NHAMCS, all diagnoses included,  United 
States National Ambulatory Medical Care Survey 
(NAMCS) and the outpatient department portions 
of the National Hospital Ambulatory Medical Care 
Survey (NHAMCS),  N = 2860 
9% Increased association:  
Age < 65 years   
Diagnosis of psychosis 
No significant association: 




Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Limited data set,  scope and validity affected 
Outpatient study in specific care systems, 
generalisability affected 




Inpatients treated with at least one antipsychotic 
in 2006, all diagnoses included, psychiatric 
inpatient unit at Royo Villanova Hospital, Zaragoza, 





Increased  association: 
Diagnosis of schizophrenia 
LAI use 
Co-morbid substance use 
disorder 
 
FGA-SGA (specific agent 
combinations not given) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Limited data set,  scope and validity affected 
Multivariate analysis not performed, results not 
adjusted for confounding 
Single centre hospital study, generalisability affected 




Outpatients prescribed antipsychotics in 
outpatient clinic in Sept 2005 - Sept 2006, all 
diagnoses included, Zonguldak Karaelmas 
University, Medical Faculty Hospital, Department 
of Psychiatry, Turkey, N = 444 
6.3% Increased association: 
Unmarried 
Diagnosis of psychosis 





Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Focused on antipsychotic prescription patterns in 
general and characteristics of patients prescribed 
different drug classes, main focus not APP 
Limited data set, scope and validity affected 
Multivariate analysis not performed on APP data, 
results not adjusted for confounding 





Barbui et al. 
2006 
Longitudinal Outpatients with diagnosis of schizophrenia with 
clinical instability receiving antipsychotic 
medication recruited from psychiatric services 
serving  four geographical catchment areas , 
Croydon (UK), Verona (Italy), Amsterdam 
(Netherlands), and Leipzig (Germany), part of a 
bigger international European clinical trial, the 
QUATRO study, N = 375 
Baseline: 23% 
Persistent use 




APP at admission 
Higher total dose of 
antipsychotic 
Decreased association: 
Number of antipsychotic 
drugs received the 12 
months before enrolment 
in study 









FGA-SGA (specific agent 
combinations not given) 
Small study size 
Participants recruited  first interviewed and only 
included if gave written, informed consent,  potential 
source of bias 
Outpatient study in schizophrenic patients with clinical 
instability, generalizability affected 
Recruiting sites not randomly selected, part of a bigger 
international European clinical trial, the QUATRO 




Longitudinal Outpatients regularly prescribed antipsychotics in 
the Catalan Health Service  during 2007, all 
diagnoses included, Barcelona Health Region, 
Catalonia, northeast Spain, N = 71004 
13.9% Not examined FGA-SGA, SGA-SGA 
(haloperidol-risperidone, 
risperidone-quetiapine) 
Limited data set, scope and validity affected 
Examined antipsychotic prescription patterns in 
general and focused on use of clozapine and depot 
antipsychotics, main focus not APP 
Associations with APP not measured in statistical 
analysis 
Study population excluded patients prescribed 










Inpatients receiving antipsychotics at discharge 
from Jan 1998 to Dec 2003, regardless of 
diagnosis, voluntary psychiatric inpatient facility in 
Ferrara, northern Italy, N = 358 





Earlier illness onset 
Diagnosis of schizophrenia 
APP at admission 
Higher illness severity 
Higher total dose of 
antipsychotic 
Decreased association: 
Antidepressant use at 
admission 
No significant association: 
Education 
Living with family 
Co-morbid substance use  
Benzodiazepine use at 
admission 
Mood stabilizer use at 
admission 
Not examined Medication examined at time of discharge, factors such 
as switching between antipsychotics may have affected 
results 
Small study size 
Inpatients admitted on voluntary basis, potential 
source of bias 
Severity scores interviewer-dependent, potential 
source of bias 
Single centre hospital study, generalizability affected 




Inpatients prescribed antipsychotics on a single 
day in June 2004, all diagnoses included, 13 French 
psychiatric hospitals, members of the PIC network, 
N = 2192 
49.3% Not examined FGA-SGA (cyamemazine-
risperidone) 
Cross-sectional study, factors such as switching 
between antipsychotics  may have affected results 
Examined antipsychotic prescription patterns in 
general and focused on factors associated with SGA 
use compared to FGA use,  main focus not APP 
Limited data set, scope and validity affected 
Single day duration, validity affected 





Inpatients prescribed antipsychotics for at least 3 
consecutive days between March 1 and May 31, 
2004, selected from computer-based pharmacy 
records using a computerized random-selection 
algorithm, all diagnoses included, McLean 
Psychiatric Hospital in Belmont, Massachusetts, 
USA, N = 305 
23.3% Increased association: 
Diagnosis of 
schizoaffective disorder 
Higher total dose of 
antipsychotic 
Co-prescription of mood 
stabilizer 




Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Computerized random sampling method used to select 
participants, details thereof not given, potential source 
of bias 
Limited data set, scope and validity affected 
Short duration of study,  validity  affected 










1995 paid Medicaid claims used to identify 
beneficiaries with diagnosis of schizophrenia and 
schizoaffective disorder, filled prescriptions for this 
group tracked over the subsequent 5 years, from 1 
Jan 1995 to 31 Dec 1999, New Hamshire Medicaid 
pharmaceutical claims database, N = 836 
Dec 1995: 5.7% 
Dec 1999: 
24.3% 
Not examined FGA-SGA (specific agent 
combinations not given) 
Point prevalence observations, factors such as 
switching between antipsychotics may have affected 
results 
Examined  prescription patterns in general, main focus 
not APP 
Relatively small study size 
Limited data set, scope and validity affected 
Single state study, participants under full Medicaid 




review   
Articles reporting on associations between APP 
and study design, patient, illness, treatment and 
prescriber characteristics,  electronic search in 
















Earlier illness onset 
Longer illness duration  
Greater illness 
acuity/severity 
Less illness insight 
Treatment resistance 
Hospitalization 
Longer inpatient stay 
Longer treatment duration 
APP at admission 






Not examined Descriptive review of studies, statistical analysis of 
findings not performed 
Studies included in review generally did not focus on 
correlates of APP, but rather on reporting prevalence - 
the reported associations likely did not capture all 
possible associations because such analyses were 
either not done or not reported in studies 
Most studies collected data on only some of the 
potential and relevant correlates, there has not been a 
comprehensive screening for all potential associations 
Many studies were cross-sectional in design and may 
have included ongoing antipsychotic switches 
Study commented on factors associated with APP but 
was often vague with regard to whether the 
associations were positive or negative 
44 
 






Random sample of outpatients in the Connecticut 
state mental health system with continuous 
prescription records  from 7/1996 to 6/1998 with 
diagnosis of schizophrenia, Connecticut state 
public mental health system,  N = 400 (total),  N = 
369 (snapshot) 
11% (snapshot) Increased association: 
High school diploma 
Unmarried 




FGA-SGA (specific agent 
combinations not given) 
Complicated study design with longitudinal and cross-
sectional component, difficult to  follow and interpret 
study results 
Focused on antipsychotic prescription patterns in 
general and characteristics of patients prescribed  
atypical agents and had medication changes, main 
focus not APP 
Small study size 
Prevalence of APP  clearly reported in cross-sectional 
"snapshot" component only 
Method of random sampling used to select participants 
not explained, potential source of bias 
Participants limited to diagnosis of schizophrenia, 
other diagnoses not included  
Outpatient population, generalizability affected 




Sample of randomly selected patients hospitalized 
for 28 days or longer between 2002 and 2005 with 
the diagnosis of psychosis, Institute of Psychiatry, 
Clinical Centre of Serbia (University hospital) in 
Belgrade, Serbia, N = 198 
67.7% Decreased association: 
More prior admissions 
 
No significant association: 
Age 
Gender 
Duration of hospitalization 
FGA-FGA (specific agent 
combinations not given) 
 
 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Method of random sampling used to select participants 
not explained, potential source of bias 
Limited data set, scope and validity affected 
Single day duration, validity affected 
Multivariate analysis not performed, results not 
adjusted for confounding 







Inpatients with diagnosis of schizophrenia 
hospitalized  in the years 1989, 1995, 1998, 2001, 
Department of Psychiatry of the Medical 





Not examined SGA-SGA, FGA-SGA 
(amisulpiride-clozapine, 
haloperidol-clozapine) 
Cross-sectional examination of discharge prescriptions, 
factors such as switching between antipsychotics may 
have affected results 
Examined prescription patterns in general, including 
polypharmacy, types of antipsychotics prescribed and 
dosing regimens, main focus not APP 
Relatively small study size 
Unclear definition of APP, no details given as to which 
agents were included as "high potency"   
Rates not comparable to studies which include all 
agents regardless of potency 








Articles published between 1970  and 05/2009 
reporting frequency of APP in patients aged > 18 
years, electronic search in PubMed and Google 
scholar to assess prevalence and correlates of APP 
across decades and regions, N = 147 
Pooled median 
APP rate of 












Study origin in Asia, 
Europe and countries 
other than North America 
Decreased association:  
Longer length of follow up 
Co-prescription of 
antidepressant 
No significant association: 
Race 
Sex 
Severity rating scores 
Clozapine use 




Decade of study 
FGA-SGA (specific agent 
combinations not given) 
Studies had heterogeneous design, population 
characteristics,  health care systems and treatment 
cultures 
Majority of studies included used cross-sectional APP 
definition, factors such as switching between 
antipsychotics may have affected results 
Many studies included did not focus on APP or 
reported with too little specificity, reducing the 
amount of data for meta-regression 
APP rates were heterogeneous between and within 
geographical location, limited generalizability of 
individual study results 
Ganguly et 
al. 2004 
Longitudinal Medicaid beneficiaries with diagnosis of 
schizophrenia with filled prescriptions for 
antipsychotics between 1998 and 2000, California 
and Georgia Medicaid pharmaceutical claims 
database, N = 31435 
Total APP: 40% 
Long-term APP: 
23% 
Increased association:  








FGA-SGA (specific agent 
combinations not given) 
Limited data set, scope and validity affected 
Study limited to 2 states, participants under full 





Case-control Inpatients discharged on more than one regularly 
scheduled antipsychotic between 1 July 2008 - 31 
August 2009, with comparison group of randomly 
selected adult patients discharged from the unit 
during this time who were not on multiple 
antipsychotics at time of discharge, Massachusetts 
General Hospital inpatient psychiatric unit, Boston, 
US, APP group N =  75, Comparison group N = 114 
N/A Increased association:  
Longer inpatient stay 
Department of mental 
health client 
Department of mental 
health supported housing 
Public or no insurance 
More than five prior 
hospitalizations 
Diagnosis of psychotic 
disorder 
Antipsychotic use on 
admission 
APP on admission 








Study group consisted of cross-sectional sample, 
factors such switching between antipsychotics at time 
of discharge may have affected results 
Small study size 
Limited data sets, scope and validity affected 
Case-control study, methods of random selection of 
control group not provided and groups were not 
matched on baseline variables 
Multivariate analysis not performed, results not 
adjusted for confounding 
Single centre hospital study, generalisability affected 
Humberston
e et a.l 2004 
Cross-
sectional 
All active outpatient files for the month of March 
2000 reviewed and outpatients prescribed an 
antipsychotic included, all community mental 
health services in Auckland, N = 3178 
16.4% Not examined Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined antipsychotic prescription patterns in 
general, main focus not APP 
Limited data set, scope and validity affected 




Longitundinal Inpatients receiving at least one antipsychotic 
medication for 28 days or longer during the year 
1999, New York State Office of Mental Health 
psychiatric hospital system,  N = 7482 inpatient 
episodes 
37.3% Increased association: 
Younger age 
African-American race (vs 
White and Hispanic) 
Previous hospitalization 
Diagnosis of psychotic 
disorder 
No significant association: 
Sex 
FGA-SGA (specific agent 
combinations not given) 
28 day overlap criterion, results may have been 
affected by very slow cross tapers 
Limited data sets, scope and validity affected 
Multivariate analysis not performed, results not 
adjusted for confounding 








Patients with diagnosis of schizophrenia 
discharged  from September-December 2011, six 
psychiatric hospitals in Poland, N = 207 
47.3% Increased association: 
Higher number of previous 
admissions 
No significant association: 
Age 
Sex 
Duration of illness 
Duration of present 
hospitalization 
Severity of symptoms 
Degree of clinical 
improvement 
FGA-SGA (specific agents 
combinations not 
reported) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Limited data set, scope and validity affected 
Severity of symptoms at admission and improvement 
on treatment assessed post hoc by psychiatrist of 
ward, potential source of bias 
Scanty information provided on study methods and 
statistical analysis 
Multivariate analysis not performed, results not 
adjusted for confounding 
Inpatient hospital study,  generalisability affected 




Inpatients with diagnosis of schizophrenia and 
schizoaffective disorder at discharge in 2010, 
Bentley Mental Health Service, Western Australia, 
N = 229 
43.2% Increased association: 
Longer inpatient stay 
No significant association: 
Age 
Sex 
Diagnosis of schizophrenia 
compared to 
schizoaffective disorder 
Co-prescription of other 
psychotropics and general 
medical drugs 
Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Limited data set, scope and validity affected 
Multivariate analysis not performed, results not 
adjusted for confounding 
Antipsychotic prescription patterns not reported 
explicitly, difficult to interpret information on 
prescriptions 






Patients with registered antipsychotic 
prescriptions  on a given date, regardless of 
diagnosis, two psychiatric hospitals in Norway, N = 
174 
Hospital A: 30% 
Hospital B: 27% 
Not examined FGA-SGA (specific agent 
combinations not given) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined antipsychotic prescription patterns  in 
general, including  types of antipsychotics prescribed 
and co-prescription patterns, main focus not APP 
Small study size 
Limited data set, scope and validity affected 
Inpatient hospital study,  generalisability affected 




Xhosa inpatients and outpatients with 
schizophrenia or schizoaffective disorder receiving 
treatment in the three areas interviewed between 
2002 and 2005, catchment areas of three state 
psychiatric hospitals and their affiliated 
community healthcare clinics in the greater 
metropole of Cape Town, N = 510 
28.6% Not examined FGA-FGA (haloperidol-
fluphenazine LAI) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined prescription patterns, including clozapine, 
haloperidol and depot use, main focus not APP 
Relatively small study size, power affected 
Population restricted to Xhosa patients, generalizability 
affected 
Kreyenbuhl 
et al. 2006 
Longitudinal Veterans with diagnosis of schizophrenia and 
schizoaffective disorder prescribed antipsychotics 
in 2000, VA facilities across the United States, data 
from VA's National Psychosis Registry, services 
provided to veterans with psychotic disorders in 
VA facilities across the US, N = 61257 





30-59 days: 20% 
Not examined FGA-SGA (haloperidol-
olanzapine) 
Limited data set, scope and validity affected 
Use of LAIs not available on records, potential source 
of bias 
Study conducted in VA system,  predominantly male 





et al. 2007 
Longitudinal Veterans with diagnosis of schizophrenia and 
schizoaffective disorder prescribed antipsychotics 
for 90 days or more in 2000,  VA facilities across 
the United States, data from VA's National 
Psychosis Registry, services provided to veterans 
with psychotic disorders in VA facilities across the 
US, N = 61257 









in past year 
More outpatient mental 
health visits  






compared to white race 
Co-morbid depression 
Co-morbid substance use 
disorder  
Medical co-morbidity 





Not examined Limited data set, scope and validity affected 
Use of LAIs not available on records, potential source 
of bias 
Study conducted in VA system,  predominantly male 
population and single system of care, generalizability 
affected 




Inpatients of acute psychiatric wards with 
diagnosis of schizophrenia discharged on 
antipsychotics during a 3 month period in 2005, 19 
participating Norwegian hospitals, N = 449 
35.6% Increased association: 
Younger age 
Inpatient treatment during 
previous 12 months 
Co-morbid personality 
disorder 
No significant association: 
Sex 




Outpatient treatment in 
previous 12 months 




FGA-SGA (specific agent 
combinations not given) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Limited data set, scope and validity affected 
Severity scores at admission dependent on interviewer, 
potential source of bias 
Portion of patients in study transferred to longer stay 
wards, prescription at final discharge from inpatient 
treatment could differ from current study results 




Latimer et al. 
2014 
Longitudinal Patients with diagnosis of schizophrenia with 
public medical claims for antipsychotic 
prescriptions covering at least 11 months during 
2004, Quebec province, Canada, N = 12150 





No significant association: 
Sex 
Public assistance receipt 
Hospital assigned 
Hospital type 
Not examined Limited data set, scope and validity affected 
Restricted to public health care medical claims, private 
system excluded, generalisability affected 
Li et al. 2015 Cross-
sectional 
Inpatients and outpatients with diagnosis of 
schizophrenia receiving antipsychotics during 
July/Aug 2012, 45 psychiatric hospitals  in China, N 
= 4239 
34.2% Increased association: 
Earlier illness onset 
Higher severity scores 
Higher total dose of 
antipsychotic 
FGA use 
Decreased association:  
Co-prescription of 
benzodiazepine  
Patient and family 
satisfaction 
No significant association: 
Age 
Sex 
Longer illness duration  
Inpatient treatment 
Having insurance 
Living with family 
Family history of 
psychiatric disorders 
Delusions or hallucinations 




SGA-SGA (specific agent 
combinations not given) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Limited data set, scope and validity affected 
Patients unable to understand contents of survey 
excluded, potential source of bias 
Hospital based study, generalisability affected 
Lopez de 




Inpatients with one or more antipsychotic 
prescription on 29 March 2011, Psychiatric 
hospital in Basque Country, Spain, N = 172 
47.1% Increased association: 
Younger age 
Male sex 






Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size  
Limited data set, scope and validity affected 
Single day duration, validity affected 
Multivariate analysis not performed, results not 
adjusted for confounding 
Single centre hospital study, generalisability affected 
50 
 




Inpatients receiving antipsychotics  during 1989, 
1999 and 2002, regardless of diagnosis, Psychiatry 
Department of Milan’s Ospedale Maggiore 




Not examined FGA-SGA (haloperidol-
risperidone) (2002) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Compared antipsychotic prescription patterns  in 
general and high-dose prescribing in 1989,1999 and 
2002, main focus not APP 
Limited data set, scope and validity affected 
Difficult to follow and interpret findings, inconsistent 
reporting of results 
Inpatient hospital study, generalisability affected 




Psychiatric inpatients hospitalized during 1995 and 
2000, Woodhull Medical and Mental Health 
Centre, Brooklyn, New York, 1995: N =  459,  2000: 
N = 584 
1995: 0% 
2000: 15.9% 
Not examined FGA-SGA (haloperidol-
olanzapine) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined  prescription patterns in general, main focus 
not APP 
Relatively small study size 
Limited data set, scope and validity affected 






Inpatients receiving antipsychotics during Feb to 
April 2008, regardless of diagnosis, Hillmorton 
Hospital and Seagar Clinic in Christchurch, New 
Zealand, N = 201 
31% Increased association:  
Male sex 
Longer inpatient stay 
Co-prescription of 
anticholinergic agent 
Diagnosis of schizophrenia 
Higher total dose of 
antipsychotic 
No significant association: 
Age 
Ethnicity 
History of type 2 diabetes  
Treatment for raised 
cholesterol/triglyceride 
Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Limited data set, scope and validity affected 
Multivariate analysis not performed, results not 
adjusted for confounding 






Longitudinal Medicaid beneficiaries with diagnosis of 
schizophrenia with filled prescriptions for 
antipsychotics between 1998 and 2003, California, 
Nebraska, Oregon, Utah and Wyoming Medicaid 
pharmaceutical claims database, N = 55481 
6.4% 
(prevalence of 






Asian race compared to 
white 




Diagnosis of schizophrenia 
Decreased association: 
Age > 34 
Initiated on olanzapine 
Initiated on risperidone 
No significant association: 
Co-morbid substance use 
disorder 
Diagnosis of depression 
Diagnosis of bipolar 
disorder 
Initiated on clozapine 
Initiated on quetiapine 
Not examined Limited data set, scope and validity affected 
California represented majority  of sample, although 
considered in data analysis methods and reporting, 
may have  affect generalizability 
Participants under full Medicaid insurance, 
generalizability affected 
Nielsen et al. 
2010 
Longitudinal Patients diagnosed with first-episode of 
schizophrenia from Jan 1996 – Dec 2006, followed 
for observation period of 1 year following initial 
diagnosis, Danish Central Psychiatric Research 
Registry ,  N = 13600 
"Total 
polypharmacy": 
33.3% in 1996, 
56.2% in 2005 
"Long-term 
polypharmacy": 
16.7% in 1996, 
37.1% in 2005 
Not examined 1996 & 1997: FGA-FGA  
1998 - 2005: FGA-SGA 
(specific agent 
combinations not given) 
 
Examined  prescription patterns  broadly, main focus 
not APP 
Unclear graphical presentation of prevalence rates, 
individual prevalence rates only provided in written 
content for 1996 and 2005 
Examined APP in first-episode schizophrenia only, 
generalizability affected 






All non-geriatric patients discharged between 1 
January and 31 December 2000, regardless of 
diagnosis, Department of Psychiatry, Riverview 









Not examined Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 
Limited data set, scope and validity affected 





Longitudinal Outpatients receiving the same prescription for at 
least 90 days, community mental health services, 













Not examined Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Relatively small study size 
Limited data set, scope and validity affected 
Outpatient study in single province in Canada, 
generalisability affected 




Inpatients with diagnosis of schizophrenia in July 
2001, inpatient psychiatry units in 6 East Asian 
countries and territories (China, Hong Kong, Japan, 













Longer illness duration 
Decreased association:  
Nil 
No significant association: 
Sex 
Psychiatric compared to 




Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Heterogeneous data sets, scope and validity affected 
Inpatient hospital study,  generalisability affected 




Inpatients with diagnosis of schizophrenia 
admitted during July 2001, Institute of Mental 
Health/Woodbridge Hospital, Singapore, N = 300 
71.7% Increases association: 
High potency antipsychotic 
use  
Co-prescription of 
anticholinergic agent  
Younger age 
Longer illness duration 
Higher total dose of 
antipsychotic 
No significant association: 
Sex 
SGA use 
Illness severity score 
Not examined Cross-sectional study, factors such switching between 
antipsychotics may have affected results 
Small study size, power affected 
Short duration, validity affected 
Limited data sets, scope and validity affected 








All patients in Finland who had at least one 
hospitalization due to schizophrenia during the 
years 2000-2007, Finnish National Hospital 
Discharge Register, N = 16083 
46.2% Increased association: 
Male sex 
Longer inpatient stay 
Previous antipsychotic use 
No significant association: 
Age 
Previous anxiolytic, 





Not examined Cross-sectional study, factors such as slow switching 
between antipsychotics may have affected results 
Limited data set, scope and validity affected 
Population consisted of patients with previous hospital 
admissions during the time period examined, 
generalizability affected 
Sun et al. 
2014 
Longitudinal Patients with schizophrenia or psychotic disorder 
with data from relevant systems, over 2005-2009 
from VA system and 2002-2009 for other systems, 
Veterans Affairs' health care system (national data 
VA database), non-federal outpatient settings 
(national data from National Ambulatory Medical 
Care Survey), two large not-for profit healthcare 
systems in southwestern and Great Lakes areas of 
the US (data from Health Maintenance 
Organization Research Network Virtual Data 
Warehouse), VA selection: N = 119662, VA one-
week selection: N = 47100, NAMS selection: N =  
885 visits, (17596617 patients represented) 
HMORN site 1 selection: N = 699, HMORN site 2 









HMORN site 1: 
16-26% 
HMORN site 2: 
21-26% 
Increased association: 
Increased rates of 1-year 
admission (VA and 
HMORN samples - NAMCS 
lacked this data) 
 
No other factors 
consistently associated 
across systems 
SGA-SGA (specific agent 
combinations not given) 
Limited data sets, scope and validity affected 
Different levels of data available in different databases, 
may have contributed to differences in APP rates 
observed 
Data available on sample characteristics differed across 
studies and limited comparability 
Data only available for VA system for 2005-2009 




Patients with diagnosis of schizophrenia receiving 
the same antipsychotic medication for the past 6 
months, 4 governmental primary psychiatric 
healthcare centres in West Bank, Gaza Strip and 
East Jerusalem territories of Palestine, N = 250 




Higher total dose of 
antipsychotic 









Number of hospitalizations 
Family history of diabetes 
SGA use 
FGA-FGA (specific agent 
combinations not given) 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Small study size 






Longitudinal Outpatients visiting one of the participating sites 
for the first time between 1 Jan 2007 and 30 June 
2008 and diagnosed with schizophrenia, 4 
psychiatric clinics in Tokyo, Japan, N = 300 
43.7% Not examined FGA-SGA 
(chlorpromazine-
risperidone) 
Study vague and difficult to follow at times 
Small study size 
Limited data set, scope and validity affected 
Significant drop out rate, reasons included loss to 
follow-up, referral to another clinic/hospital and 
hospitalization, potential source of bias 
Outpatient study with limited population,  
generalisability affected 




Patients with diagnosis of schizophrenia or other 
psychotic disorder under the care of randomly 
recruited or volunteer psychiatrists participating in 
the PRN Study, 3 patients from each psychiatrist 
randomly selected from a patient log, 1997 
American Psychiatric Association Practice Research 
Network (PRN) Data, N = 155 
17% Not examined Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined antipsychotic prescription patterns with 
focus on use of newer antipsychotics, main focus not 
APP 
Small study size 
Methods of random sampling used to select 
participants not provided, potential source of bias 
Psychiatrists in study randomly selected and self-
volunteers, potential source of bias 
Participants restricted to those under care of 
psychiatrists involved in study, generalizability affected 




Patients with diagnosis of schizophrenia or other 
psychotic disorder under the care of randomly 
recruited or volunteer psychiatrists participating in 
the PRN Study, 3 patients from each psychiatrist 
randomly selected from a patient log, 1999 
American Psychiatric Association Practice Research 
Network (PRN) Data, N = 151 
16% Not examined Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined treatment patterns in general, including 
pharmacologic and psychosocial treatment, main focus 
not APP 
Small study size 
Methods of random sampling used to select 
participants not provided, potential source of bias 
Psychiatrists in study randomly selected and self-
volunteers, potential source of bias 
Participants restricted to those under care of 





Outpatients with diagnosis of schizophrenia or 
schizoaffective disorder prescribed an 
antipsychotic at each of the three time points in 
study, 2 urban mental health service catchment 
areas of Auckland, Australia, March 2000: N =  








Not examined Not examined Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Examined antipsychotic prescription patterns in 
general, main focus not APP 
Limited data set, scope and validity affected 









Clinically stable outpatients with schizophrenia, 
random selection methods used, 2 psychiatric 
outpatient clinics at university-affiliated hospitals 
in Beijing and Hong Kong, N = 505 





No significant association: 
Age 
Number of hospitalizations 




Not examined Study vague and difficult to follow at times 
Cross-sectional study, factors such as switching 
between antipsychotics may have affected results 
Relatively small study size 
Limited data set, scope and validity affected 
Methods of random sampling used to select 
participants not provided, potential source of bias 
Population limited to clinically stable hospital 
outpatients in two of China's most developed cities, 
generalisability affected 







Inpatients with schizophrenia, examined in 2001, 
2004 and 2009, hospitals in 9 Asian countries and 

















2004 & 2009: FGA-SGA 
 
(specific agent 
combinations not given) 
Cross-sectional samples in study, factors such as 
switching between antipsychotics may have affected 
results 
Limited data set, scope and validity affected 
Study centres differed in some sites across the three 
time periods examined, may have distorted 
comparisons 
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Background: Antipsychotic polypharmacy (APP) appears to be a common practice worldwide 
despite lack of evidence for efficacy and treatment guidelines advising against the practice for most 
patients.  Our study aimed to address deficiencies in local and international research by examining 
the current prevalence of APP in a South African context and investigating a broad range of patient, 
illness and treatment characteristics that may be associated with the practice. 
Methods:  We conducted a cross-sectional study of discharge records using Valkenberg Hospital’s 
electronic patient database.  We collected data on patient, illness and treatment characteristics for 
patients discharged on one or more antipsychotic agents from January to June 2014. Hierarchical 
multivariable logistic regression analysis was used to assess the relationship between demographic 
and clinical variables and APP. We also analysed psychotropic co-prescription patterns associated 
with APP.  
Results: Discharge records of 565 patients were examined. The prevalence of APP in our study 
population was 29.03% (95% CI= 25.31%-32.96%). Analysis of demographic and clinical 
characteristics revealed that age>29, male sex, diagnosis of schizophrenia compared to bipolar and 
substance-induced disorders, co-morbid intellectual disability, co-morbid substance use, greater 
number of hospital admissions and high-dose prescribing were significantly  associated with APP. 
While highest rates of APP occurred in patients with schizophrenia and schizoaffective disorders, 
APP was also observed in a number of patients with bipolar and substance-induced disorders. 
Prescription patterns demonstrated the prominent use of first-generation antipsychotics and long 
acting injectable preparations in APP combinations. Patients receiving APP were significantly more 
likely to have anticholinergic agents and sodium valproate co-prescribed in their treatment regimen.  
Conclusions: Our study suggests that current local practice deviates from standard local and 
international guidelines in that combination antipsychotic agents are prescribed for a number of 
patients with a range of psychiatric diagnoses and symptoms without sufficient evidence for efficacy 
of this practice and at possible cost of increased adverse effects.  Patients receiving APP may be 
those with greater illness severity, complexity, chronicity and treatment resistance, with 
complicating factors including co-morbid substance use involved. Antipsychotic prescription patterns 





Antipsychotics, polypharmacy, antipsychotic combination, psychiatric hospital  
1 Background  
Antipsychotic agents are used in the treatment of psychotic and mood disorders. Local and 
international clinical practice guidelines for the treatment of schizophrenia (1,2) advocate an 
approach of antipsychotic monotherapy in the majority of cases.  Guidelines recommend avoiding 
antipsychotic polypharmacy (APP) which can be defined as co-prescription of more than one 
antipsychotic drug for a given patient,(3) except for short periods when switching agents or in 
treatment resistant cases, when augmentation of clozapine with another antipsychotic agent may be 
considered, although supporting evidence for this remains weak.(4,5) Treatment guidelines 
recommend use of antipsychotics as part of treatment options in bipolar disorder but do not 
advocate an approach of APP.(6,7) Use of antipsychotic agents in the treatment of psychosis with 
coexisting substance misuse is advised in accordance with the individual guidelines on schizophrenia 
or bipolar disorder.(8)  
Motivation behind guidelines is the lack of robust evidence to support the routine use of combined 
antipsychotics.(3-5,9,10) In addition, there is evidence for harm associated with APP. Research has 
shown an association of APP with increased adverse effects including extrapyramidal side-
effects,(11-13) hyperprolactinaemia,(14-16)  sexual dysfunction,(17) hypersalivation,(18) 
sedation,(14) cognitive impairment,(19) and diabetes.(20,21) Possible increased risk of sudden 
cardiac death (22) and mortality (23,24) has been suggested.  Additional concerns have been drug-
drug interactions, problems in determining cause and effect of different treatments, complex drug 
regimens resulting in decreased compliance and greater cost.(25)  
Despite these adverse aspects, APP appears to be a common practice worldwide. A recent 
systematic review found a global median prevalence of APP of 19.6% across time, with factors such 
as clinical setting, geographical location and time of study influencing prevalence rates.(26)  In 
contrast to the fairly substantial international literature on APP, there is a paucity of research on APP 
from Africa, with only one previous study examining rates of APP in a South African setting 
conducted in 2008.(27) There is clearly a need for investigation into this practice in the current South 




Research into factors contributing to the practice of APP has shown that antipsychotic prescription 
patterns reflect complex interplay among patient, illness, treatment and prescriber factors.(25)  
However, inconsistencies and gaps in the evidence remain.  Patient characteristics of age, sex and 
marital status have received most attention, with fewer studies examining other patient factors 
possibly associated with APP. There is a lack of information on illness characteristics in the context of 
APP.  APP is a practice generally examined in the context of schizophrenia/schizoaffective disorders, 
with fewer studies investigating the occurrence of APP in bipolar disorder and no previous studies 
examining APP rates in substance-induced disorders found. There is a deficiency in the literature on 
co-morbidities associated with APP. Antipsychotic prescriptions seem to vary widely in different 
contexts and there is a need for further studies investigating associations with concomitant 
psychotropic prescriptions.  Moreover, there have been no previous studies examining patient, 
illness and treatment characteristics associated with APP in South Africa. 
Our study attempted to address these deficiencies in local and international research by examining 
the current prevalence of APP in a South African context and investigating a broad range of patient, 
illness and treatment characteristics that may be associated with this practice. In doing so, we were 
able to assess whether current local practice is comparable with standard local and international 
guidelines. We examined antipsychotic prescribing patterns across diagnoses, including bipolar 
disorder and substance-induced disorders. We provided insight into the prevalence of and factors 
associated with APP in a study population in the Western Cape, increasing understanding of the 
complexity of the practice of APP in our setting.   
 
2 Methods  
 
2.1 Study aims 
 
We aimed to determine the prevalence of APP in patients discharged from Valkenberg Hospital and 
examine the patient, illness and treatment factors associated with APP compared to monotherapy.  
 
2.2 Sample and setting 
 
We conducted our study at Valkenberg Hospital, a large, government-funded psychiatric hospital in 
the suburb of Observatory, in Cape Town, South Africa.  The hospital provides psychiatric services to 
the Cape Peninsula and is a major specialist referral centre of the Western Cape Province. It is the 
principal teaching hospital for the University of Cape Town’s Department of Psychiatry. The hospital 
60 
 
currently comprises 340 inpatient beds, of which 200 are dedicated to acute psychiatric services, 125 
to forensic psychiatric services and 15 to a smaller therapeutic component. Patients admitted to the 
acute psychiatric units are commonly involuntary admissions under the Mental Health Care Act 
(2002) with severe mental illness posing a risk to themselves or others and are unable to be 
managed on an outpatient basis.  
We performed a cross-sectional study of discharge records using Valkenberg Hospital’s electronic 
patient record database (Clinicom). The study was approved by the University of Cape Town’s 
Human Research Ethics Committee, the Faculty of Health Sciences and the Department of Health. 
Data were collected for patients with serious mental illness prescribed one or more antipsychotic 
agents at the time of discharge from Valkenberg Hospital’s acute and therapeutic units. We 
extracted discharge information for patients with diagnoses including schizophrenia (F20), acute and 
transient psychotic disorder (F23), delusional disorder (F22) schizoaffective disorder (F25), 
substance-induced mood and psychotic disorders (F10 - F19) and bipolar disorder (F31). We 
excluded patients with primary diagnoses relating to a medical condition, dementia, anxiety 
disorder, major depressive disorder, intellectual disability or personality disorder as these diagnoses 
were unlikely to feature significantly in our study population or contribute meaningfully to rates of 
APP in our setting.  We examined the time period of January to June 2014.  
2.3 Data and variables extracted 
We used an electronic data extraction form to extract data from the electronic discharge database. 
Patient variables including age, gender, marital status and occupation of patients discharged on one 
or more antipsychotic agent were collected. These variables were routinely documented on the 
record database at time of admission. 
Illness variables of length of hospital stay (measured in days from admission to discharge date), 
number of Valkenberg hospital admissions and time from first hospitalization at Valkenberg to most 
recent discharge (as approximate indicator of illness duration or time in treatment) were retrieved 
from the database.  
Patient diagnoses recorded in the database using ICD-10 coding methods were collected. Data on co-
morbid psychiatric conditions were gathered both from ICD-10 coding and information contained in 
discharge summaries completed electronically for each patient by their attending psychiatric 
registrar at time of discharge. Where the attending case manager commented on the presence of 




traits or mild intellectual disability, these were captured as psychiatric co-morbidities. Diagnoses and 
associated clinical features are discussed routinely (typically over 4-8 clinical case discussion ward 
rounds on average over the admission period) by members of a multidisciplinary team under 
consultant psychiatrist supervision and include multiple sources of information. All diagnoses are 
confirmed by a consultant psychiatrist in charge of each multidisciplinary team. Discharge records 
are routinely audited by consultant psychiatrists. Data on co-morbid substance use was likewise 
gathered from ICD-10 coding and clinical descriptors within patient discharge summaries. These 
included co-morbid alcohol (F10), cannabis (F12), methamphetamine (F15), methaqualone (F13), 
heroin (F11) and cocaine (F14) misuse.  
Antipsychotic agents prescribed at discharge were recorded in patient discharge summaries and 
captured according to names, dosages, types of agents and route of administration. Agents classified 
by type as first-generation antipsychotics (FGAs) included haloperidol, chlorpromazine, 
trifluoperazine, flupentixol, zuclopenthixol and fluphenazine. Second-generation antipsychotics 
(SGAs) included amisulpiride, clozapine, olanzapine, risperidone, quetiapine and aripiprazole.  Route 
of administration was captured as oral or long acting injectable (LAI). APP was defined as the 
prescription of any 2 or more antipsychotics on discharge from hospital in the same patient. To 
compare doses of different antipsychotic drugs, the prescribed daily dose (PDD) in milligrams was 
divided by the defined daily dose (DDD) to give a PDD:DDD ratio. The DDD is defined as the assumed 
average maintenance dose per day for a drug used for its main indication in adults.(28)  For LAIs, the 
DDD is based on the average recommended dose divided by the dosing interval.(28) This is the 
standard international unit recommended by the World Health Organization for drug utilization 
studies.(28) In keeping with previous studies, the PDD/DDD ratio for APP was calculated as the sum 
of the individual PDD/DDD ratios of all antipsychotics prescribed to a patient and high-dose 
prescribing was defined as PDD/DDD of greater than 1.5.(29-31) In addition to antipsychotic agents, 
data on co-prescription of anticholinergic agents, mood stabilizers, antidepressants and 
benzodiazepines were captured.  
2.4 Statistical analysis  
We inspected data for normality using histograms and Shapiro Wilks’ test for normality. Continuous 
variables were analysed using student’s t-test or for normal data and Wilcoxon-ranksum test for 
skewed data. For categorical variables we used Chi-square tests to analyse data, with Fisher’s exact 
test where appropriate. Confidence intervals for prevalence rates were calculated using the normal 
approximation of the binomial distribution.  
62 
 
The main outcome of interest was the presence of antipsychotic polypharmacy (APP), as previously 
defined. We coded a positive outcome (i.e. the presence of APP) as “1” and a negative (no APP) as 
“0”. We conducted a hierarchical multivariable logistic regression analysis in order to model the 
response variable of antipsychotic polypharmacy as a function of a number of demographic and 
clinical variables. Independent (predictor) variables were categorised into multilevel categorical 
variables using dummy coding to obtain reference level categories. Cut-points for continuous 
variables were decided on the basis of what constituted meaningful clinical categorisations.  We 
followed a forward selection and backward elimination procedure and determined model fit using a 
combination of Likelihood-ratio Chi-square tests and the Akaike Information Criterion (AIC). We 
entered each variable into the model one at a time starting with demographic and then clinical 
variables. We removed variables one at a time if model fit did not improve by their addition, based 
on the likelihood Chi-square tests and AIC. The final model included all variables except reported 
symptoms of anxiety and depression and length of inpatient stay. Model fit for the final model was 
determined using the Pearson Chi-Square Goodness of Fit test. Statistical significance was set at 
p<0.05. We used Stata version 13 for Windows to analyse the data. 
3 Results  
 
3.1 Antipsychotic polypharmacy:  Prevalence, clinical and demographic associations 
A total of 567 patient records met criteria for inclusion. We excluded 2 records where patients were 
diagnosed with acute and transient symptoms of psychosis (F23) and delusional disorder (F22), as 
these patients were low in number, resulting in a final sample of N=565.  Of the total sample 60.71% 
were male and the median age was 32 (IQR: 25-32). 
The prevalence of APP among our study population was 29.03% (95% CI= 25.31%-32.96%). The 
demographic and clinical characteristics of patients discharged on APP and antipsychotic 
monotherapy (APM) are shown in Table 1, with results of multivariable analyses examining 
associations between these characteristics and the likelihood of receiving APP reported as adjusted 
odds ratios (AOR). Patients in age category 30–44 were significantly more likely to receive APP than 
those in age category 18–29 (AOR=2.90, CI=1.65–5.11, p<0 .001), as were those aged 45–60 years 
(AOR=2.28, CI=1.06–4.90, p = 0.033). The odds of receiving APP was significantly higher in males 
(AOR=1.93, CI=1.09–3.41, p=0.023) and approached significance at the 5% level in patients who 
were unemployed (AOR=10.05, CI=0.82–121.90, p=0.070).  There were no significant associations 




from those who were single (AOR=0.43, CI=0.11-1.64, p=0.219 and AOR=0.48, CI=0.04–5.47, p=0.560 
respectively), and neither did those who were divorced (AOR=2.02, CI=0.65–6.27, p=0.220).  
When compared to patients with schizophrenia, patients with other diagnoses were less likely to 
receive APP, with an AOR of 0.55 for schizoaffective disorder (CI=0.27–1.14, p=0.111), and a 
significantly lower odds for APP of 0.32 for bipolar disorder (CI=0.15–0.65, p=0.002) and 0.40 for 
substance-induced disorder (CI=0.91–0.87, p=0.021). APP was more likely in patients with co-morbid 
personality disorders (AOR=2.50, CI=0.89–7.11, p=0.080), with this association approaching 
significance at the 5% level. Intellectual disability (AOR=3.94, CI=1.39–11.15, p=0.010), and 
substance use (AOR=1.82, CI=1.02–3.22, p=0.040) were both associated with a significant increased 
odds of APP. Co-morbid depressive and anxiety symptoms were not significantly associated  with 
APP (not shown and omitted from model).  
There was no significant association between illness duration and APP (measured as time from first 
admission to most recent discharge) for either patients with between 1-3 years of illness duration 
(AOR=0.85, CI=0.37–1.92, p=0.701) or patients with >3 years (AOR=1.05, CI=0.44–2.48, p=0.907)   
compared to those with illness duration of <1 year. Compared to patients with <3 prior admissions 
to Valkenberg hospital, the odds increased of having APP in those with higher numbers of 
Valkenberg admissions, with the AOR of 2.13 for patients with 3-6 admissions (CI =0.98–4.64, 
p=0.055), which approached statistical significance and 2.64 for patients with >6 admissions 
(CI=1.05–6.62, p=0.038), a statistically significant difference. Length of hospital stay did not show 






Characteristic Adjusted OR 95% CI P value
N % N %
Demographic
Age (years)
18 - 29 (reference) 52 31.71 187 46.63 ref (1.0) ref ref
30 - 44 81 49.39 135 33.67 2.90 1.65 - 5.11 < 0.001
45 - 60 31 18.90 79 19.70 2.28 1.06 - 4.90 0.033
Sex
Female (reference) 38 23.17 184 45.89 ref (1.0) ref ref
Male 126 76.83 217 54.11 1.93 1.09 - 3.41 0.023
Marital status 
single (reference) 151 92.07 345 86.03 ref (1.0) ref ref
married 3 1.83 33 8.23 0.43 0.11 - 1.64 0.219
divorced 9 5.49 17 4.24 2.02 0.65 - 6.27 0.220
widowed 1 0.61 6 1.50 0.48 0.04 - 5.47 0.560
Occupation
Employment (reference) 1 0.61 25 6.23 ref (1.0) ref ref
Unemployed 164 99.39 376 93.77 10.05 0.82 - 121.90 0.070
Clinical 
Diagnosis
Schizophrenia (reference) 93 56.71 145 36.16 ref (1.0) ref ref
Schizoaffective disorder 36 21.95 43 10.72 0.55 0.27 - 1.14 0.111
Bipolar disorder 20 12.20 112 27.93 0.32 0.15 - 0.65 0.002
Substance-induced disorder 15 9.15 101 25.19 0.40 0.91 - 0.87 0.021
Psychiatric co-morbidities
Personality disorder
No personality disorder (reference) 152 92.68 385 96.01 ref (1.0) ref ref
Personality disorder 12 7.32 16 3.99 2.50 0.89 - 7.11 0.080
Intellectual disability
No intellectual disability (reference) 152 92.68 390 97.26 ref (1.0) ref ref
Intellectual disability 12 7.32 11 2.74 3.94 1.39 - 11.15 0.010
Substance use 
No substance use (reference) 58 42.48 182 45.39 ref (1.0) ref ref
Substance use 219 54.61 106 64.63 1.82 1.02 - 3.22 0.040
Time from first admission to last dischargre (illness duration) (years)
0 - 1 (reference) 39 23.78 208 51.67 ref (1.0) ref ref
1 - 3 26 15.85 74 18.45 0.85 0.37 - 1.92 0.701
> 3 99 60.37 119 29.68 1.05 0.44 - 2.48 0.907
Number of Valkenberg admissions 
< 3 (reference) 53 32.32 260 64.84 ref (1.0) ref ref
3-6 50 30.49 92 22.94 2.13 0.98 - 4.64 0.055
> 6 61 37.20 49 12.22 2.64 1.05 - 6.62 0.038
High-dose prescribing 
No high-dose prescribing (reference) 81 49.39 378 94.26 ref (1.0) ref ref
High-dose prescribing 83 50.61 23 5.74 11.34 6.20 - 20.74 < 0.001
APP APM
Table 1 Comparison of demographic and clinical characteristics of patients discharged on antipsychotic polypharmacy (APP) and 




3.2 Frequency, dosing and different types antipsychotic combinations 
Prescription rates of individual antipsychotic agents are shown in Table 2. Of the 164 participants 
who were prescribed 2 or more antipsychotics, the majority (N= 161, 97.56%) were prescribed 2 
antipsychotics and only 3 patients (2.44%) were prescribed 3 different antipsychotics. The most 
commonly prescribed agent amongst all patients discharged was haloperidol (36.64%), followed by 
risperidone oral preparation (27.96%) and zuclopenthixol LAI (17.17%). The most common agents 
among patients discharged on APM were haloperidol (35.91%), risperidone oral (31.67%) and 
olanzapine (7.48%). In those discharged on APP, zuclopenthixol LAI was prescribed in 50% of 
patients, followed by haloperidol (38.41%), flupentixol LAI (29.88%), risperidone oral (18.90%) and 
clozapine (16.46%). When associations were examined, APP was found to be significantly associated 
with use of flupentixol LAI (p<0.001), zuclopenthixol LAI (p<0.001), fluphenazine LAI (p<0.001), 
amisulpiride (p<0.001), clozapine (p=0.001), chlorpromazine (p=0.003) and risperidone oral 
preparation (p=0.002).  The odds of APP was significantly higher with high-dose prescribing 
(AOR=11.34, CI=6.20–20.74, p<0.001).  
 
The frequency of antipsychotic combinations prescribed at discharge is demonstrated in Table 3. The 
most common combination of antipsychotics was that of haloperidol and zuclopenthixol LAI, found 
in as many as 22.56 % of patients discharged on APP.  This was followed by the haloperidol and 
flupentixol LAI combination which was present in 9.76% of combinations, chlorpromazine and 
Test- statistic df P-value
N % N % N %
FGA
Haloperidol 63 38.41 144 35.91 207 36.64 Chi-square = 0.31 1 0.575
Chlorpromazine 22 13.41 24 5.99 46 8.14 Chi-square = 8.59 1 0.003
Trifluoperazine 7 4.27 14 3.49 21 3.72 Chi-square = 0.19 1 0.658
Flupentixol (LAI) 49 29.88 7 1.75 56 9.91 Chi-square = 103.16 1 < 0.001
Zuclopenthixol  (LAI) 82 50.00 15 3.74 97 17.17 Chi-square = 175.15 1 < 0.001
Fluphenazine (LAI) 22 13.41 3 0.75 25 4.42 Chi-square = 44.15 1 < 0.001
SGA
Amisulpiride 13 7.93 4 1 17 3.01 Fisher's exact test - < 0.001
Clozapine 27 16.46 28 6.98 55 9.73 Chi-square = 11.90 1 0.001
Olanzapine 12 7.32 30 7.48 42 7.43 Chi-square = 0.00 1 0.946
Risperidone (oral) 31 18.90 127 31.67 158 27.96 Chi-square = 9.42 1 0.002
Risperidone (LAI) 1 0.61 3 0.75 4 0.71 Fisher's exact test - NS
Quetiapine 2 1.22 1 0.25 3 0.53 Fisher's exact test - 0.203
Aripiprazole 0 0 1 0.25 1 0.18 Fisher's exact test - NS
NS = Non-significant (p>0.05)
APP APMAntipsychotic Total
Table 2 Antipsychotics prescribed to patients discharged on antipsychotic polypharmacy (APP) and 
antipsychotic monotherapy (APM)  (N=565)
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zuclopenthixol LAI in 8.54%, risperidone oral and flupentixol LAI in 7.93% and risperidone oral with 
zuclopenthixol LAI found in 7.32% of patients discharged on APP.  
Table 3 Antipsychotic combinations in patients 
with antipsychotic polypharmacy (APP) at 
discharge (N=164) 
Antipsychotic combination  N % 
Haloperidol + Zuclopenthixol (LAI) 37 22.56 
Haloperidol + Flupentixol (LAI) 16 9.76 
Chlorpromazine + Zuclopenthixol (LAI) 14 8.54 
Risperidone (oral) + Flupentixol (LAI) 13 7.93 
Risperidone (oral) + Zuclopenthixol 
(LAI) 12 7.32 
Amisulpiride + Clozapine 9 5.49 
Haloperdiol + Fluphenazine (LAI) 9 5.49 
Clozapine + Zuclopenthixol (LAI) 7 4.27 
Olanzapine + Zuclopenthixol (LAI) 7 4.27 
Chlorpromazine + Flupentixol (LAI) 6 3.66 
Olanzapine + Flupentixol (LAI) 5 3.05 
Clozapine + Flupentixol (LAI) 4 2.44 
Clozapine + Fluphenazine (LAI) 4 2.44 
Risperidone + Fluphenazine (LAI) 4 2.44 
Trifluoperazine + Fluphenazine (LAI) 3 1.83 
Trifluoperazine + Zuclopenthixol (LAI) 2 1.22 
Trifluoperazine + Flupentixol (LAI) 2 1.22 
Chlorpromazine + Fluphenazine (LAI) 2 1.22 
Haloperidol + Risperidone (oral) 1 0.61 
Amisulpiride + Zuclopenthixol (LAI) 1 0.61 
Quetiapine + Flupentixol (LAI) 1 0.61 
Quetiapine + Zuclopenthixol (LAI) 1 0.61 
Risperidone (oral) + Risperidone (LAI) 1 0.61 
Amisulpiride + Clozapine + Flupentixol 
(LAI) 2 1.21 
Amisulpiride + Clozapine + 
Zuclopenthixol (LAI) 1 0.60 
 
As regards the nature of combinations according to type of antipsychotic agent class and route of 
administration, FGA oral and FGA LAI combinations predominated, being found in 55.49% of patients 
discharged on APP, followed by SGA oral and  FGA LAI in 35.97% and a combination of 2 SGA oral 








3.3 Co-prescriptions of other psychotropic medications with APP 
Psychotropic co-prescriptions are displayed in Table 5. Anticholinergic agents, given to 44.51% of 
patients on APP regimens and 27.93% of patients receiving APM, were highly significantly associated 
with APP (P<0.001). In turn, sodium valproate also demonstrated a significant association with APP, 
being co-prescribed in as many as 53.05% of patients receiving APP, compared with 41.15% of 
patients prescribed APM (p=0.010). Lithium was significantly more commonly co-prescribed 
amongst patients on APM (16.71%) compared to patients on APP (9.76%) (p=0.034). Additional 
subgroup exploratory analysis confined to patients with APP (N=164) demonstrated a significant 
association between diagnosis and valproate co-prescription (p<0.001), with as many as 40.23% of 
sodium valproate co-prescriptions occurring in patients with diagnosis of schizophrenia, followed by 
34.48% in schizoaffective disorder, only 17.24% in bipolar disorder and 8.05% in substance-induced 
disorders. Lithium co-prescriptions in those receiving APP occurred only in patients with diagnoses of 
bipolar and schizoaffective disorder, each contributing 50% of the total. Fluoxetine was the most 
frequently co-prescribed antidepressant, appearing in 3.66% of patients discharged on APP and 
2.74% on AMP, but no significant associations between antidepressant co-prescriptions and APP 
were found. Similarly, benzodiazepines were prescribed to 4.88% of patients receiving APP and 
7.48% of those on APM, a non-significant association.  
Type and route of administration N %
FGA (oral) + FGA (oral) 0 0
FGA (oral) + FGA (LAI) 91 55.49
FGA (oral) + SGA (oral) 1 0.61
FGA (oral) + SGA (LAI) 0 0
SGA (oral) + SGA (oral) 9 5.49
SGA (oral) + SGA (LAI) 1 0.61
SGA (oral) + FGA (LAI) 59 35.97
SGA (oral) + SGA (oral) + FGA (LAI) 3 1.82
Table 4 Antipsychotic combination types in 
patients with antipsychotic polypharmacy 




4 Discussion  
The APP prevalence rate of 29.03% found in our study is fairly high in comparison to international 
rates, with a recent systematic review finding a global median prevalence of APP of 19.6% across 
time.(26) Our finding of a relatively high APP prevalence of 29.03% is similar to that of an earlier 
South African study published in 2008. This study reviewed data on antipsychotic drug prescriptions 
for Xhosa patients with schizophrenia and schizoaffective disorder, particularly in terms of clozapine 
use and found that there was an overall low rate (10%) of clozapine use and a relatively high 
frequency of APP (28.6% of patients).(27) The study suggested that high rates of APP may have been 
partially explained by high rates of LAI use (49.4% of patients), with the most frequently used 
antipsychotic combination used being haloperidol and a LAI (54.2% of combinations). While this 
study investigated APP in a limited population, our study examined the practice amongst all patients 
discharged on antipsychotic agents, without restricting race or diagnosis. Although findings were 
similar, our analysis of antipsychotic drug prescriptions examined prescription patterns in greater 
detail and included several additional SGAs that were not widely available in the South African public 
sector at the time of the previous study. In addition, we examined APP in the context of a range of 
patient, illness and treatment factors, increasing understanding of the complexity of the practice of 
APP in our setting.  
Our study thus provides insight into various aspects that require consideration in relation to our 
relatively high rate of APP.  The associations of APP with clinical and demographic characteristics 
Test- statistic df P-value
N % N % N %
Anticholinergic 73 44.51 112 27.93 185 32.74 Chi-square = 14.53 1 0.001
Mood stabilizer
Sodium valproate 87 53.05 165 41.15 252 44.6 Chi-square = 6.67 1 0.010
Lithium 16 9.76 67 16.71 83 14.69 Chi-square = 4.48 1 0.034
Lamotrigine 1 0.61 2 0.50 3 0.53 Fisher's exact test - NS
Carbamazepine 1 0.61 2 0.50 3 0.53 Fisher's exact test - NS
Topiramate 0 0 1 0.25 1 0.18 Fisher's exact test - NS
Antidepressant 
Amitriptyline 0 0 1 0.25 1 0.18 Fisher's exact test - NS
Clomipramine 0 0 1 0.25 1 0.18 Fisher's exact test - NS
Citalopram 2 1.22 5 1.25 7 1.24 Fisher's exact test - NS
Fluoxetine 6 3.66 11 2.74 17 3.01 Fisher's exact test - 0.591
Venlafaxine 1 0.61 0 0 1 0.18 Fisher's exact test - 0.290
Benzodiazepine 8 4.88 30 7.48 38 6.73 Chi-square = 1.25 1 0.262
NS = Non-significant (p>0.05)
Psychotropic co-prescription APP APM Total
Table 5 Psychotropics co-prescribed to patients discharged on antipsychotic polypharmacy (APP) 




was statistically significant for age>29, male sex, diagnosis of schizophrenia compared to bipolar and 
substance-induced disorders, co-morbid intellectual disability, co-morbid substance use and greater 
number of hospital admissions.  The positive association of APP with increased age is of interest in 
that it contrasts to data from several international studies that have showed an association of APP 
with younger age.(25) It is possible that older patients hospitalized in our setting are those with 
greater illness severity, complexity, chronicity and treatment resistance, factors which have been 
found to be associated with APP (25,26), with additional antipsychotics possibly added as a result of 
poor response on monotherapy. Likewise, the associations of APP with male sex and greater number 
of hospital admissions could also be linked to greater illness severity, complexity, chronicity and 
refractoriness in these patients,(25) as could the association with intellectual disability, with similar 
findings in previous studies and suggestion that individuals suffering from intellectual disability may 
be poorly responsive to antipsychotic treatments.(32)  
While highest rates of APP in patients with diagnoses of schizophrenia and schizoaffective disorder 
were anticipated, it was of interest that APP was also observed in a fair number of patients with 
bipolar disorder and several patients with substance-induced disorders. Co-prescription of sodium 
valproate showed a significant positive association with APP, occurring significantly more often in 
APP patients with diagnoses of schizophrenia and schizoaffective disorders. In addition to its mood 
stabilizing action, sodium valproate may be used to treat residual psychotic symptoms and 
aggression in some cases.(11) There was a significant positive association between co-morbid 
substance use and APP, on a background of high rates of substance use in our population.  It is 
evident that APP is a practice that warrants further investigation across diagnoses with careful 
attention to various contributing factors that could be targeted for intervention, including substance 
use.  
Prescription patterns demonstrated the prominent use of FGAs and LAI formulations in APP 
combinations, which is in keeping with previous local and international literature.(26,27) However, 
our finding of FGA (oral) and FGA (LAI) predominantly used together in combinations differed from 
international trends that have demonstrated a move from FGA-FGA combinations to more FGA-SGA 
combinations over time, with FGA-SGA combination treatment being most common in recent 
studies.(26) FGAs remain common first-line prescriptions in our population, their lower cost making 
them particularly attractive in a resource-limited setting.  SGA agents remain second-line choices in 
many cases, with restricted availability of certain agents including quetiapine and aripiprazole. LAIs 
are commonly used. They may frequently be added to existing regimens where concerns over 
compliance exist, contributing to their significant association with APP. In other cases, the positive 
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association of APP with use of LAIs may result from the difficulty performing fine adjustments with 
LAIs alone, leading to oral medication being added for this purpose.(25) Often, oral medication is 
used as initial lead in dosing for the first few weeks after LAI initiation while waiting for LAI plasma 
levels to reach steady state.  As there is evidence that eventual discontinuation of the oral 
medication in such cases is often deferred and may even continue beyond its original purpose as 
lead-in medication,(33) an important aspect of treatment planning would include instructions to 
community clinics to taper and stop such medications and audits of whether such processes are in 
fact carried out. The majority of combinations found in our study remain unsupported by evidence, 
with the possible exception of clozapine augmentation strategies.(3,4)  
The positive association of APP with clozapine and use of clozapine with amisulpiride in 
combinations recorded demonstrates attempts by some prescribers to follow treatment guidelines 
in managing treatment resistant patients.  However, the rates of clozapine use in our study 
population (9.7%) remain relatively low in comparison to international rates.(34-37) Possible reasons 
for this include clinician concerns about treatment adherence, side-effect profile, the need for 
regular follow-up for monitoring of leukocyte counts required with clozapine treatment and 
difficulties related to reintroduction of clozapine after discontinuation for longer than 48 hours.(27)  
The results of our study also contribute to concern over the safety of APP. There was a significant 
positive association of APP with high-dose prescribing, as well as with co-prescription of 
anticholinergic medication. This may suggest risk for increased extrapyramidal side-effects with APP, 
which in turn raises concerns about potential additional adverse effects possibly resulting from 
excess dopamine D2 blockade, including akathisia, tardive dyskinesia and hyperprolactinaemia 
amongst others.(11)  
Our study does however have several limitations that should be noted when interpreting results. 
Restriction to a single centre hospital population may have produced results that may not be readily 
generalizable to the general population, with inpatient status found to be associated with APP in 
previous studies.(25) While discharge prescriptions should have reflected the plan for ongoing 
maintenance treatment in most patients, some APP may have resulted from certain patients 
discharged during a process of cross titration while changing antipsychotic agents or with oral 
medication being used as lead-in dosing with initiation of LAI as discussed. In addition, our study was 
cross-sectional  in nature, with variables examined being limited to administrative data and 
information contained in discharge summaries completed electronically for each patient by their 




failed to document co-morbid psychiatric symptoms or substance use. We did not extract 
information from case files on sequential antipsychotic medications used and reasons for medication 
changes during hospital stay, making it uncertain whether prescribing of the combination was 
preceded by failure trials of monotherapy in hospital. Certain relevant variables were not directly 
recorded. We attempted to overcome this problem by examining related variables. Length of time 
from first hospitalization to most recent discharge was used to provide some indication of duration 
of illness or time in treatment, although we acknowledge that the patient may have been diagnosed 
with mental illness prior to first hospital admission. Number of previous admissions and length of 
stay were recorded as indicators of illness severity and possibly treatment resistance, although we 
realize that these are not direct substitute measures.  
5 Conclusion 
 
Our study suggests that current local practice deviates from standard local and international 
guidelines in that combination antipsychotic agents are prescribed for a number of patients with a 
range of psychiatric diagnoses without evidence for this practice, and at possible cost of increased 
adverse effects. Our findings indicate that antipsychotic prescription patterns reflect a complex 
interplay among patient, illness and treatment characteristics of our population. Additional research 
is needed examining the practice of APP across diagnoses, focusing on the multiple aspects affecting 
local practice and various contributing factors that could be targeted for intervention.  This would be 
a positive step towards improving the quality of our service in order to advance mental health care 
practice and provide optimal patient management in a resource-limited setting.  
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service team at info@biomedcentral.com. 
5 Preparing tables 
When preparing tables, please follow the formatting instructions below. 
 Tables should be numbered and cited in the text in sequence using Arabic numerals (i.e. 
Table 1, Table 2 etc.). 
 Tables less than one A4 or Letter page in length can be placed in the appropriate location 
within the manuscript. 
 Tables larger than one A4 or Letter page in length can be placed at the end of the document 
text file. Please cite and indicate where the table should appear at the relevant location in 
the text file so that the table can be added in the correct place during production. 
 Larger datasets, or tables too wide for A4 or Letter landscape page can be uploaded as 
additional files. Please see [below] for more information. 
 Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or 
comma separated values (.csv). Please use the standard file extensions. 
 Table titles (max 15 words) should be included above the table, and legends (max 300 
words) should be included underneath the table. 
 Tables should not be embedded as figures or spreadsheet files, but should be formatted 
using ‘Table object’ function in your word processing program. 
 Color and shading may not be used. Parts of the table can be highlighted using superscript, 
numbering, lettering, symbols or bold text, the meaning of which should be explained in a 
table legend. 
 Commas should not be used to indicate numerical values. 
If you have any questions or are experiencing a problem with tables, please contact the customer 
service team at info@biomedcentral.com. 
6 Preparing additional files 
As the length and quantity of data is not restricted for many article types, authors can provide 
datasets, tables, movies, or other information as additional files. 
All Additional files will be published along with the accepted article. Do not include files such as 
patient consent forms, certificates of language editing, or revised versions of the main manuscript 
document with tracked changes. Such files, if requested, should be sent by email to the journal’s 




Results that would otherwise be indicated as "data not shown" should be included as additional files. 
Since many web links and URLs rapidly become broken, BioMed Central requires that supporting 
data are included as additional files, or deposited in a recognized repository. Please do not link to 
data on a personal/departmental website. Do not include any individual participant details. The 
maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission. 
Each additional file should be cited in sequence within the main body of text. 
 
